Ignite Creation Date:
2025-12-24 @ 11:43 PM
Ignite Modification Date:
2025-12-30 @ 8:07 PM
Study NCT ID:
NCT01243151
Status:
COMPLETED
Last Update Posted:
2019-01-22
First Post:
2010-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006937', 'term': 'Hypercholesterolemia'}, {'id': 'D050171', 'term': 'Dyslipidemias'}], 'ancestors': [{'id': 'D006949', 'term': 'Hyperlipidemias'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000598888', 'term': 'bococizumab'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'description': 'The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non serious in another participant, or one participant may have experienced both a serious and non serious event during the study.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.', 'otherNumAtRisk': 12, 'otherNumAffected': 9, 'seriousNumAtRisk': 12, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.', 'otherNumAtRisk': 14, 'otherNumAffected': 8, 'seriousNumAtRisk': 14, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.', 'otherNumAtRisk': 14, 'otherNumAffected': 5, 'seriousNumAtRisk': 14, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'PF-04950615 1.00 mg/kg', 'description': 'Participants recieved a single dose of PF-04950615 1.0 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.', 'otherNumAtRisk': 13, 'otherNumAffected': 7, 'seriousNumAtRisk': 13, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.', 'otherNumAtRisk': 14, 'otherNumAffected': 9, 'seriousNumAtRisk': 14, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Iron deficiency anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Atrioventricular block first degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Bundle branch block left', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Application site dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Energy increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Influenza like illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Infusion site extravasation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Non-cardiac chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Puncture site haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Vessel puncture site haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Vessel puncture site haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Folliculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Fungal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Arthropod sting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Epicondylitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Excoriation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Infusion related reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Liver function test abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'QRS axis abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Muscular weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Musculoskeletal stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Hyperventilation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Angioedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Dermatitis contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Ecchymosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}], 'seriousEvents': [{'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 15.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Dose Limiting and Intolerable Treatment-Related Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'With dose limiting treatment related AEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'With intolerable treatment related AEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Dose limiting and intolerable treatment-related AEs were the AEs resulting from drug overdose, drug withdrawal, drug abuse, drug misuse, drug interactions, drug dependency, extravasation, exposure in utero, exposure during breast feeding.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-Related Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Treatment emergent AEs', 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}]}]}, {'title': 'Treatment emergent SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Treatment related AEs', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to Day 78 that were absent before treatment or that worsened relative to pretreatment state.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Adverse Events (AEs) by Severity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Grade 1', 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}]}, {'title': 'Grade 2', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}]}]}, {'title': 'Grade 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Grade 4', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Grade 5', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug. AE was assessed according to common terminology criteria for adverse events (CTCAE) version 4.0 severity grades- Grade 1: mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2: moderate (minimal, local or non invasive intervention indicated); Grade 3: severe (medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling); Grade 4: Life-threatening consequences; urgent intervention indicated and Grade 5: Death related to AE.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'Criteria: Haemoglobin(Hgb), hematocrit, RBC: \\<0.8\\*lower limit of normal(LLN),mean corpuscular volume, mean corpuscular Hgb concentration \\<0.9\\*LLN or\\>1.1\\*upper limit of normal(ULN), platelet\\<0.5\\*LLN or\\>1.75\\*ULN, WBC\\<0.6\\*LLN or\\>1.5\\*ULN, lymphocyte, neutrophil\\<0.8\\*LLN or\\>1.2\\*ULN, basophil, eosinophil, monocyte\\>1.2\\*ULN; bilirubin\\>1.5\\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase, lactate dehydrogenase\\>3.0\\*ULN,total protein,albumin\\<0.8\\*LLN or\\>1.2\\*ULN; blood urea nitrogen, creatinine\\>1.3\\*ULN,uric acid\\>1.2\\*ULN;sodium\\<0.95\\*LLNor\\>1.05\\*ULN,potassium,chloride,calcium,bicarbonate\\<0.9\\*LLN or\\>1.1\\*ULN; glucose\\<0.6\\*LLN or \\>1.5\\*ULN, urine specific gravity\\<1.003 or\\>1.030,urine pH\\<4.5or\\>8,urine glucose, ketones, urine protein,urine blood/Hgb,urobilinogen,bilirubin,nitrite, leukocyte esterase\\>=1; urine RBC,WBC\\>=20,urine epithelial cells\\>=6,urine granular casts,hyaline casts\\>1,urine bacteria\\>20,partial thromboplastin time,prothrombin:\\>1.1\\*ULN.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Clinically Relevant Changes in Vital Signs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Supine SBP', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Maximum IFB in standing SBP', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'Maximum IFB in supine DBP', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Maximum IFB in standing DBP', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Maximum DFB in supine SBP', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Maximum DFB in standing SBP', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Maximum DFB in supine DBP', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}]}]}, {'title': 'Maximum DFB in standing DBP', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Standing SBP', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}]}]}, {'title': 'Supine DBP', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Standing DBP', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Supine Pulse Rate', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Standing Pulse Rate', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Maximum IFB in supine SBP', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'Criteria for clinically relevant vital signs: supine and standing systolic blood pressure (SBP): less than (\\<) 90 millimeter of mercury (mmHg); supine and standing diastolic blood pressure (DBP): \\<50 mmHg. Maximum increase from baseline (IFB) or decrease from baseline (DFB) in supine and standing SBP: greater than or equal to (\\>=) 30 mmHg and maximum IFB or DFB in supine and standing DBP: \\>=20 mmHg. Supine pulse rate: \\<40 and greater than (\\>) 120 beats per minute (bpm); standing pulse rate: \\<40 and \\>140 bpm.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Parameters', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'PR interval: Maximum IFB', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'QRS Complex: Maximum IFB', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'QTcF Interval: Maximum IFB >=30 to <60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}, {'title': 'QTcF Interval: Maximum IFB >=60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': "Criteria for clinically relevant ECG parameters: PR interval: maximum IFB of \\>=25 percent or 50 percent; QRS complex: maximum IFB of \\>=25 or 50 percent; QTcF interval (Fridericia's Correction): maximum IFB of \\>=30 millisecond (msec) to \\<60 msec and maximum IFB of \\>=60 msec.", 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Anti-drug Antibodies (ADA)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'The number of participants with at least one positive ADA were summarized for each treatment arm. Participants with positive antibody titer of \\>4.32 milligram/milliliter (mg/mL) were considered as ADA positive.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug. Only the participants who received a dose of PF-04950615 0.25, 0.50, 1.0, and 1.50 mg/kg were planned to be analysed for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '596700', 'spread': '13', 'groupId': 'OG000'}, {'value': '1224000', 'spread': '23', 'groupId': 'OG001'}, {'value': '2697000', 'spread': '14', 'groupId': 'OG002'}, {'value': '4253000', 'spread': '18', 'groupId': 'OG003'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '749800', 'spread': '12', 'groupId': 'OG000'}, {'value': '2134000', 'spread': '22', 'groupId': 'OG001'}, {'value': '4766000', 'spread': '26', 'groupId': 'OG002'}, {'value': '8351000', 'spread': '16', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'AUCtau is area under the concentration-time profile from time zero to time tau (τ), the dosing interval, where tau =168 hours.', 'unitOfMeasure': 'nanogram*hour/ milliliter (ng*h/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacokinetic (PK) parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '6.00', 'groupId': 'OG000', 'lowerLimit': '0.883', 'upperLimit': '9.00'}, {'value': '3.61', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '24.00'}, {'value': '1.00', 'groupId': 'OG002', 'lowerLimit': '0.867', 'upperLimit': '9.18'}, {'value': '1.00', 'groupId': 'OG003', 'lowerLimit': '0.833', 'upperLimit': '24.00'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '6.00', 'groupId': 'OG000', 'lowerLimit': '0.850', 'upperLimit': '9.00'}, {'value': '1.30', 'groupId': 'OG001', 'lowerLimit': '0.867', 'upperLimit': '9.00'}, {'value': '6.00', 'groupId': 'OG002', 'lowerLimit': '0.850', 'upperLimit': '24.00'}, {'value': '6.00', 'groupId': 'OG003', 'lowerLimit': '0.850', 'upperLimit': '9.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'Tmax is the time at which maximum plasma concentration (Cmax) occurred.', 'unitOfMeasure': 'hour', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Maximum Observed Plasma Concentration (Cmax) of PF-04950615', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '8077', 'spread': '19', 'groupId': 'OG000'}, {'value': '15080', 'spread': '20', 'groupId': 'OG001'}, {'value': '31380', 'spread': '13', 'groupId': 'OG002'}, {'value': '45110', 'spread': '15', 'groupId': 'OG003'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '10170', 'spread': '11', 'groupId': 'OG000'}, {'value': '23680', 'spread': '50', 'groupId': 'OG001'}, {'value': '45820', 'spread': '17', 'groupId': 'OG002'}, {'value': '76180', 'spread': '15', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'unitOfMeasure': 'nanogram per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Plasma Decay Half-Life (t1/2) of PF-04950615', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '50.39', 'spread': '6.4231', 'groupId': 'OG000'}, {'value': '71.50', 'spread': 'NA', 'comment': 'Standard deviation was not calculated as only 1 participant was evaluable.', 'groupId': 'OG002'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '94.24', 'spread': '57.042', 'groupId': 'OG000'}, {'value': '140.4', 'spread': '45.610', 'groupId': 'OG001'}, {'value': '155.6', 'spread': '38.503', 'groupId': 'OG002'}, {'value': '247.2', 'spread': '85.361', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 't1/2 was the time measured for the plasma concentration of PF-04950615 to decrease by one half. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.', 'unitOfMeasure': 'hour', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Apparent Clearance (CL) of PF-04950615', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'categories': [{'measurements': [{'value': '28.98', 'spread': '19', 'groupId': 'OG000'}, {'value': '18.26', 'spread': '21', 'groupId': 'OG001'}, {'value': '17.59', 'spread': '26', 'groupId': 'OG002'}, {'value': '14.05', 'spread': '15', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'CL was calculated as Dose/AUCtau. AUCtau is area under the concentration-time profile from time zero to time tau, the dosing interval, where tau=168 hours.', 'unitOfMeasure': 'milliliter per hour (mL/hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here 'Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Volume of Distribution at Steady State (Vss) of PF-04950615', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'categories': [{'measurements': [{'value': '3815', 'spread': '111', 'groupId': 'OG000'}, {'value': '3221', 'spread': '20', 'groupId': 'OG001'}, {'value': '4035', 'spread': '19', 'groupId': 'OG002'}, {'value': '5285', 'spread': '25', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'Vss was calculated as CL\\*MRT. CL was calculated as Dose/AUCtau, where AUCtau was area under the concentration-time profile from time zero to time tau (τ), the dosing interval, where tau=168 hours. MRT was mean residence time (predicted) extrapolated to infinity.', 'unitOfMeasure': 'milliliter (mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here 'Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Accumulation Ratio (Rac) of PF-04950615', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.261', 'spread': '12', 'groupId': 'OG000'}, {'value': '1.685', 'spread': '11', 'groupId': 'OG001'}, {'value': '1.771', 'spread': '16', 'groupId': 'OG002'}, {'value': '1.964', 'spread': '9', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'Rac was calculated as Day 22 AUCtau divided by Day 1 AUCtau, where AUCtau is area under the concentration-time profile from time zero to time tau (τ), the dosing interval, where tau =168 hours.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here 'Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '160.96', 'spread': '19.447', 'groupId': 'OG000'}, {'value': '155.04', 'spread': '18.501', 'groupId': 'OG001'}, {'value': '160.39', 'spread': '27.326', 'groupId': 'OG002'}, {'value': '155.62', 'spread': '23.393', 'groupId': 'OG003'}, {'value': '164.00', 'spread': '21.729', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-6.59', 'spread': '11.258', 'groupId': 'OG000'}, {'value': '-58.89', 'spread': '16.313', 'groupId': 'OG001'}, {'value': '-49.08', 'spread': '12.708', 'groupId': 'OG002'}, {'value': '-68.54', 'spread': '27.477', 'groupId': 'OG003'}, {'value': '-67.96', 'spread': '27.754', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-8.21', 'spread': '20.192', 'groupId': 'OG000'}, {'value': '-77.96', 'spread': '22.181', 'groupId': 'OG001'}, {'value': '-70.38', 'spread': '25.583', 'groupId': 'OG002'}, {'value': '-93.25', 'spread': '31.287', 'groupId': 'OG003'}, {'value': '-93.79', 'spread': '23.841', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-8.96', 'spread': '21.416', 'groupId': 'OG000'}, {'value': '-84.81', 'spread': '17.345', 'groupId': 'OG001'}, {'value': '-91.69', 'spread': '20.718', 'groupId': 'OG002'}, {'value': '-101.92', 'spread': '26.974', 'groupId': 'OG003'}, {'value': '-102.21', 'spread': '27.277', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-13.71', 'spread': '17.240', 'groupId': 'OG000'}, {'value': '-82.50', 'spread': '20.848', 'groupId': 'OG001'}, {'value': '-88.00', 'spread': '25.267', 'groupId': 'OG002'}, {'value': '-104.33', 'spread': '35.026', 'groupId': 'OG003'}, {'value': '-104.21', 'spread': '26.207', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.36', 'spread': '21.969', 'groupId': 'OG000'}, {'value': '-9.73', 'spread': '19.796', 'groupId': 'OG001'}, {'value': '-10.15', 'spread': '14.174', 'groupId': 'OG002'}, {'value': '-14.09', 'spread': '38.162', 'groupId': 'OG003'}, {'value': '-65.14', 'spread': '39.500', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Square (LS) Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.68', 'ciLowerLimit': '-71.37', 'ciUpperLimit': '-37.99', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.323', 'groupDescription': 'Day 8: Analysis was performed using the analysis of covariance (ANCOVA) treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.18', 'ciLowerLimit': '-61.28', 'ciUpperLimit': '-27.08', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.530', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-64.44', 'ciLowerLimit': '-81.35', 'ciUpperLimit': '-47.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.433', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-61.75', 'ciLowerLimit': '-78.36', 'ciUpperLimit': '-45.15', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.282', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-72.16', 'ciLowerLimit': '-92.40', 'ciUpperLimit': '-51.92', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.097', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-63.89', 'ciLowerLimit': '-84.59', 'ciUpperLimit': '-43.19', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.328', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-88.69', 'ciLowerLimit': '-109.39', 'ciUpperLimit': '-68.00', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.327', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-84.65', 'ciLowerLimit': '-104.76', 'ciUpperLimit': '-64.54', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.028', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-78.47', 'ciLowerLimit': '-96.22', 'ciUpperLimit': '-60.71', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.854', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-84.45', 'ciLowerLimit': '-102.51', 'ciUpperLimit': '-66.40', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.998', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-96.08', 'ciLowerLimit': '-114.12', 'ciUpperLimit': '-78.03', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.994', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-92.33', 'ciLowerLimit': '-109.80', 'ciUpperLimit': '-74.86', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.703', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-71.41', 'ciLowerLimit': '-90.51', 'ciUpperLimit': '-52.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.534', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-76.01', 'ciLowerLimit': '-95.37', 'ciUpperLimit': '-56.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.659', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-93.78', 'ciLowerLimit': '-113.18', 'ciUpperLimit': '-74.38', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.678', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-89.58', 'ciLowerLimit': '-108.35', 'ciUpperLimit': '-70.81', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '9.362', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'milligram per deciliter (mg/dL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had atleast 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.15', 'spread': '6.983', 'groupId': 'OG000'}, {'value': '-38.53', 'spread': '11.399', 'groupId': 'OG001'}, {'value': '-31.59', 'spread': '10.032', 'groupId': 'OG002'}, {'value': '-44.24', 'spread': '17.213', 'groupId': 'OG003'}, {'value': '-40.72', 'spread': '14.210', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.39', 'spread': '12.713', 'groupId': 'OG000'}, {'value': '-50.68', 'spread': '14.566', 'groupId': 'OG001'}, {'value': '-45.47', 'spread': '17.016', 'groupId': 'OG002'}, {'value': '-59.42', 'spread': '19.934', 'groupId': 'OG003'}, {'value': '-58.02', 'spread': '16.265', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.94', 'spread': '12.826', 'groupId': 'OG000'}, {'value': '-54.66', 'spread': '9.140', 'groupId': 'OG001'}, {'value': '-58.12', 'spread': '13.891', 'groupId': 'OG002'}, {'value': '-64.59', 'spread': '13.826', 'groupId': 'OG003'}, {'value': '-62.78', 'spread': '16.665', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-8.72', 'spread': '11.074', 'groupId': 'OG000'}, {'value': '-52.96', 'spread': '11.416', 'groupId': 'OG001'}, {'value': '-55.25', 'spread': '15.133', 'groupId': 'OG002'}, {'value': '-65.50', 'spread': '17.327', 'groupId': 'OG003'}, {'value': '-63.85', 'spread': '14.416', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.97', 'spread': '13.710', 'groupId': 'OG000'}, {'value': '-5.87', 'spread': '12.391', 'groupId': 'OG001'}, {'value': '-6.50', 'spread': '9.229', 'groupId': 'OG002'}, {'value': '-6.94', 'spread': '22.385', 'groupId': 'OG003'}, {'value': '-40.47', 'spread': '25.797', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.82', 'ciLowerLimit': '-43.99', 'ciUpperLimit': '-23.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.077', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-27.93', 'ciLowerLimit': '-38.35', 'ciUpperLimit': '-17.51', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.202', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-39.59', 'ciLowerLimit': '-49.89', 'ciUpperLimit': '-29.28', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.143', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.63', 'ciLowerLimit': '-47.75', 'ciUpperLimit': '-27.51', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.051', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-45.99', 'ciLowerLimit': '-58.78', 'ciUpperLimit': '-33.20', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.384', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.82', 'ciLowerLimit': '-54.90', 'ciUpperLimit': '-28.74', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.527', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.35', 'ciLowerLimit': '-69.43', 'ciUpperLimit': '-43.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.531', 'groupDescription': 'Day 15: Analysis was performed using ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-53.45', 'ciLowerLimit': '-66.17', 'ciUpperLimit': '-40.74', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.344', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.67', 'ciLowerLimit': '-60.70', 'ciUpperLimit': '-38.64', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.498', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-53.92', 'ciLowerLimit': '-65.14', 'ciUpperLimit': '-42.70', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.592', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.60', 'ciLowerLimit': '-71.81', 'ciUpperLimit': '-49.38', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.590', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.67', 'ciLowerLimit': '-68.53', 'ciUpperLimit': '-46.80', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.413', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.18', 'ciLowerLimit': '-55.80', 'ciUpperLimit': '-32.57', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.800', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.28', 'ciLowerLimit': '-59.06', 'ciUpperLimit': '-35.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.881', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.73', 'ciLowerLimit': '-69.53', 'ciUpperLimit': '-45.94', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.891', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.96', 'ciLowerLimit': '-66.38', 'ciUpperLimit': '-43.54', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.701', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Number of Participants Achieving LDL-C Less Than (<) 70 Milligram Per Deciliter (mg/dL)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}]}]}, {'title': 'Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0472', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '24.972', 'ciLowerLimit': '1.04', 'ciUpperLimit': '599.65', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1368', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '11.815', 'ciLowerLimit': '0.46', 'ciUpperLimit': '305.54', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0190', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '47.527', 'ciLowerLimit': '1.89', 'ciUpperLimit': '1198.29', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0192', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '45.328', 'ciLowerLimit': '1.86', 'ciUpperLimit': '1103.73', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0105', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '74.273', 'ciLowerLimit': '2.74', 'ciUpperLimit': '2014.67', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0086', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '86.088', 'ciLowerLimit': '3.10', 'ciUpperLimit': '2389.27', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0084', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '87.733', 'ciLowerLimit': '3.14', 'ciUpperLimit': '2449.11', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0053', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '112.272', 'ciLowerLimit': '4.07', 'ciUpperLimit': '3097.22', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0403', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '27.697', 'ciLowerLimit': '1.16', 'ciUpperLimit': '662.20', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0361', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '30.247', 'ciLowerLimit': '1.25', 'ciUpperLimit': '733.32', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0069', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '89.341', 'ciLowerLimit': '3.43', 'ciUpperLimit': '2326.44', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0081', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '76.034', 'ciLowerLimit': '3.08', 'ciUpperLimit': '1875.15', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.9931', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.018', 'ciLowerLimit': '0.02', 'ciUpperLimit': '64.41', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0259', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '38.943', 'ciLowerLimit': '1.55', 'ciUpperLimit': '975.84', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0142', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '57.766', 'ciLowerLimit': '2.26', 'ciUpperLimit': '1477.88', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0179', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '48.734', 'ciLowerLimit': '1.95', 'ciUpperLimit': '1216.90', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 15, 22, 29 and 36', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Number of Participants Achieving LDL-C Less Than (<) 100 Milligram Per Deciliter (mg/dL)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '12', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '12', 'groupId': 'OG004'}]}]}, {'title': 'Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '12', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.0013', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '353.058', 'ciLowerLimit': '9.95', 'ciUpperLimit': '12528.19', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0047', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '129.984', 'ciLowerLimit': '4.44', 'ciUpperLimit': '3808.21', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0018', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '300.099', 'ciLowerLimit': '8.35', 'ciUpperLimit': '10787.45', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0025', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '190.835', 'ciLowerLimit': '6.34', 'ciUpperLimit': '5743.12', 'groupDescription': 'Day 15: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0018', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '255.421', 'ciLowerLimit': '7.87', 'ciUpperLimit': '8290.22', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0034', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '150.547', 'ciLowerLimit': '5.28', 'ciUpperLimit': '4291.89', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0018', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '745.542', 'ciLowerLimit': '11.60', 'ciUpperLimit': '47929.45', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0031', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '146.296', 'ciLowerLimit': '5.40', 'ciUpperLimit': '3963.01', 'groupDescription': 'Day 22: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0020', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '213.512', 'ciLowerLimit': '7.13', 'ciUpperLimit': '6396.64', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0038', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '124.439', 'ciLowerLimit': '4.73', 'ciUpperLimit': '3277.13', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0020', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '622.309', 'ciLowerLimit': '10.51', 'ciUpperLimit': '36846.03', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0017', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '224.427', 'ciLowerLimit': '7.63', 'ciUpperLimit': '6598.00', 'groupDescription': 'Day 29: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2751', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.158', 'ciLowerLimit': '0.24', 'ciUpperLimit': '161.08', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0038', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '152.977', 'ciLowerLimit': '5.05', 'ciUpperLimit': '4633.92', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0020', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '756.203', 'ciLowerLimit': '11.18', 'ciUpperLimit': '51133.53', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0021', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '258.938', 'ciLowerLimit': '7.53', 'ciUpperLimit': '8902.61', 'groupDescription': 'Day 36: Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 15, 22, 29 and 36', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Number of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in LDL-C From Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.9580', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.896', 'ciLowerLimit': '0.02', 'ciUpperLimit': '52.79', 'groupDescription': 'Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0732', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '17.375', 'ciLowerLimit': '0.76', 'ciUpperLimit': '394.65', 'groupDescription': 'Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0159', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '47.860', 'ciLowerLimit': '2.07', 'ciUpperLimit': '1109.11', 'groupDescription': 'Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0264', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '33.246', 'ciLowerLimit': '1.51', 'ciUpperLimit': '733.62', 'groupDescription': 'Logistic regression model with treatment and baseline LDL-C stratum as factors was used for the analysis.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline, Day 15, 22, 29 and 36', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '142.67', 'spread': '20.328', 'groupId': 'OG000'}, {'value': '144.43', 'spread': '20.562', 'groupId': 'OG001'}, {'value': '150.39', 'spread': '20.863', 'groupId': 'OG002'}, {'value': '143.46', 'spread': '25.005', 'groupId': 'OG003'}, {'value': '156.39', 'spread': '28.988', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.00', 'spread': '16.065', 'groupId': 'OG000'}, {'value': '1.86', 'spread': '9.698', 'groupId': 'OG001'}, {'value': '0.88', 'spread': '13.167', 'groupId': 'OG002'}, {'value': '-1.38', 'spread': '10.776', 'groupId': 'OG003'}, {'value': '-1.75', 'spread': '15.074', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.00', 'spread': '14.918', 'groupId': 'OG000'}, {'value': '13.86', 'spread': '14.032', 'groupId': 'OG001'}, {'value': '8.96', 'spread': '13.120', 'groupId': 'OG002'}, {'value': '6.83', 'spread': '13.997', 'groupId': 'OG003'}, {'value': '8.82', 'spread': '21.116', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-5.50', 'spread': '12.395', 'groupId': 'OG000'}, {'value': '5.12', 'spread': '13.477', 'groupId': 'OG001'}, {'value': '2.27', 'spread': '15.869', 'groupId': 'OG002'}, {'value': '-3.42', 'spread': '10.025', 'groupId': 'OG003'}, {'value': '6.32', 'spread': '13.546', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.58', 'spread': '12.817', 'groupId': 'OG000'}, {'value': '7.96', 'spread': '12.365', 'groupId': 'OG001'}, {'value': '2.81', 'spread': '12.377', 'groupId': 'OG002'}, {'value': '1.67', 'spread': '10.614', 'groupId': 'OG003'}, {'value': '3.68', 'spread': '16.505', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-8.92', 'spread': '11.057', 'groupId': 'OG000'}, {'value': '-8.81', 'spread': '24.972', 'groupId': 'OG001'}, {'value': '-6.35', 'spread': '13.842', 'groupId': 'OG002'}, {'value': '-5.42', 'spread': '15.639', 'groupId': 'OG003'}, {'value': '2.46', 'spread': '15.163', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.2883', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.50', 'ciLowerLimit': '-4.77', 'ciUpperLimit': '15.77', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.131', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2563', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.05', 'ciLowerLimit': '-4.51', 'ciUpperLimit': '16.61', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.277', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.7149', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.92', 'ciLowerLimit': '-8.54', 'ciUpperLimit': '12.37', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.225', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4480', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.95', 'ciLowerLimit': '-6.40', 'ciUpperLimit': '14.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.174', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0231', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '14.50', 'ciLowerLimit': '2.06', 'ciUpperLimit': '26.94', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.214', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0858', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '11.13', 'ciLowerLimit': '-1.62', 'ciUpperLimit': '23.87', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.369', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2440', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.57', 'ciLowerLimit': '-5.30', 'ciUpperLimit': '20.44', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.431', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0702', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '11.52', 'ciLowerLimit': '-0.98', 'ciUpperLimit': '24.03', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.249', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0531', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.64', 'ciLowerLimit': '-0.13', 'ciUpperLimit': '19.41', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.878', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0758', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.93', 'ciLowerLimit': '-0.96', 'ciUpperLimit': '18.83', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.940', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6965', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.95', 'ciLowerLimit': '-8.01', 'ciUpperLimit': '11.92', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.975', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0071', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '13.52', 'ciLowerLimit': '3.83', 'ciUpperLimit': '23.22', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.842', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0339', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '11.20', 'ciLowerLimit': '0.88', 'ciUpperLimit': '21.52', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.155', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1075', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.56', 'ciLowerLimit': '-1.92', 'ciUpperLimit': '19.03', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.235', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2601', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.98', 'ciLowerLimit': '-4.54', 'ciUpperLimit': '16.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.258', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0570', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.96', 'ciLowerLimit': '-0.31', 'ciUpperLimit': '20.24', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.132', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had atleast 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '126.54', 'spread': '13.662', 'groupId': 'OG000'}, {'value': '124.04', 'spread': '16.454', 'groupId': 'OG001'}, {'value': '120.32', 'spread': '16.199', 'groupId': 'OG002'}, {'value': '125.62', 'spread': '18.377', 'groupId': 'OG003'}, {'value': '119.57', 'spread': '16.804', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.79', 'spread': '15.901', 'groupId': 'OG000'}, {'value': '-38.39', 'spread': '8.150', 'groupId': 'OG001'}, {'value': '-32.69', 'spread': '11.479', 'groupId': 'OG002'}, {'value': '-46.46', 'spread': '17.016', 'groupId': 'OG003'}, {'value': '-41.36', 'spread': '12.796', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-9.21', 'spread': '10.279', 'groupId': 'OG000'}, {'value': '-49.11', 'spread': '15.713', 'groupId': 'OG001'}, {'value': '-46.00', 'spread': '19.321', 'groupId': 'OG002'}, {'value': '-61.83', 'spread': '22.850', 'groupId': 'OG003'}, {'value': '-56.29', 'spread': '14.567', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.21', 'spread': '12.520', 'groupId': 'OG000'}, {'value': '-52.54', 'spread': '13.124', 'groupId': 'OG001'}, {'value': '-52.38', 'spread': '14.826', 'groupId': 'OG002'}, {'value': '-65.17', 'spread': '21.560', 'groupId': 'OG003'}, {'value': '-59.44', 'spread': '19.275', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-8.46', 'spread': '12.945', 'groupId': 'OG000'}, {'value': '-55.54', 'spread': '14.941', 'groupId': 'OG001'}, {'value': '-54.08', 'spread': '14.850', 'groupId': 'OG002'}, {'value': '-70.75', 'spread': '25.561', 'groupId': 'OG003'}, {'value': '-63.66', 'spread': '16.555', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-8.29', 'spread': '12.894', 'groupId': 'OG000'}, {'value': '-8.46', 'spread': '18.284', 'groupId': 'OG001'}, {'value': '-9.38', 'spread': '13.489', 'groupId': 'OG002'}, {'value': '-11.92', 'spread': '17.403', 'groupId': 'OG003'}, {'value': '-39.36', 'spread': '19.171', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.88', 'ciLowerLimit': '-42.93', 'ciUpperLimit': '-22.84', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.008', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-30.80', 'ciLowerLimit': '-41.34', 'ciUpperLimit': '-20.26', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.260', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-39.98', 'ciLowerLimit': '-50.18', 'ciUpperLimit': '-29.77', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.088', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.37', 'ciLowerLimit': '-48.54', 'ciUpperLimit': '-28.20', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.070', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-42.18', 'ciLowerLimit': '-54.73', 'ciUpperLimit': '-29.63', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.271', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-42.69', 'ciLowerLimit': '-55.72', 'ciUpperLimit': '-29.67', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.512', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.56', 'ciLowerLimit': '-67.45', 'ciUpperLimit': '-41.67', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.445', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-51.89', 'ciLowerLimit': '-64.54', 'ciUpperLimit': '-39.25', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.321', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '95', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.35', 'ciLowerLimit': '-58.10', 'ciUpperLimit': '-36.59', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.359', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-51.08', 'ciLowerLimit': '-62.24', 'ciUpperLimit': '-39.91', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.566', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.89', 'ciLowerLimit': '-70.89', 'ciUpperLimit': '-48.89', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.482', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.03', 'ciLowerLimit': '-67.83', 'ciUpperLimit': '-46.24', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.377', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.06', 'ciLowerLimit': '-60.61', 'ciUpperLimit': '-37.51', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.767', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-51.52', 'ciLowerLimit': '-63.48', 'ciUpperLimit': '-39.56', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.974', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-64.22', 'ciLowerLimit': '-76.04', 'ciUpperLimit': '-52.40', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.901', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.01', 'ciLowerLimit': '-71.59', 'ciUpperLimit': '-48.42', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.785', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '237.75', 'spread': '24.940', 'groupId': 'OG000'}, {'value': '233.21', 'spread': '26.471', 'groupId': 'OG001'}, {'value': '239.36', 'spread': '32.827', 'groupId': 'OG002'}, {'value': '242.54', 'spread': '31.408', 'groupId': 'OG003'}, {'value': '247.21', 'spread': '24.410', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-8.67', 'spread': '12.841', 'groupId': 'OG000'}, {'value': '-61.29', 'spread': '18.605', 'groupId': 'OG001'}, {'value': '-51.96', 'spread': '18.394', 'groupId': 'OG002'}, {'value': '-77.15', 'spread': '28.981', 'groupId': 'OG003'}, {'value': '-71.50', 'spread': '28.657', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-11.33', 'spread': '23.714', 'groupId': 'OG000'}, {'value': '-77.43', 'spread': '22.270', 'groupId': 'OG001'}, {'value': '-70.96', 'spread': '30.673', 'groupId': 'OG002'}, {'value': '-97.67', 'spread': '35.386', 'groupId': 'OG003'}, {'value': '-94.79', 'spread': '24.196', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.58', 'spread': '24.265', 'groupId': 'OG000'}, {'value': '-85.00', 'spread': '21.184', 'groupId': 'OG001'}, {'value': '-89.81', 'spread': '23.173', 'groupId': 'OG002'}, {'value': '-112.08', 'spread': '36.393', 'groupId': 'OG003'}, {'value': '-100.14', 'spread': '26.658', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-14.67', 'spread': '17.127', 'groupId': 'OG000'}, {'value': '-83.46', 'spread': '23.107', 'groupId': 'OG001'}, {'value': '-88.35', 'spread': '26.534', 'groupId': 'OG002'}, {'value': '-116.75', 'spread': '46.591', 'groupId': 'OG003'}, {'value': '-104.14', 'spread': '26.623', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.25', 'spread': '19.760', 'groupId': 'OG000'}, {'value': '-11.38', 'spread': '31.685', 'groupId': 'OG001'}, {'value': '-11.88', 'spread': '20.431', 'groupId': 'OG002'}, {'value': '-16.42', 'spread': '35.522', 'groupId': 'OG003'}, {'value': '-63.64', 'spread': '40.832', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.91', 'ciLowerLimit': '-75.54', 'ciUpperLimit': '-34.29', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.392', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.07', 'ciLowerLimit': '-65.21', 'ciUpperLimit': '-22.94', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.646', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-67.98', 'ciLowerLimit': '-88.92', 'ciUpperLimit': '-47.05', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.547', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.51', 'ciLowerLimit': '-81.11', 'ciUpperLimit': '-39.90', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.381', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-68.39', 'ciLowerLimit': '-89.02', 'ciUpperLimit': '-47.76', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.392', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.41', 'ciLowerLimit': '-81.54', 'ciUpperLimit': '-39.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.646', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-86.60', 'ciLowerLimit': '-107.74', 'ciUpperLimit': '-65.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.656', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-81.13', 'ciLowerLimit': '-101.73', 'ciUpperLimit': '-60.52', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.381', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-80.16', 'ciLowerLimit': '-100.96', 'ciUpperLimit': '-59.37', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.479', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-83.00', 'ciLowerLimit': '-104.14', 'ciUpperLimit': '-61.87', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.646', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-104.77', 'ciLowerLimit': '-125.91', 'ciUpperLimit': '-83.62', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.656', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-90.23', 'ciLowerLimit': '-110.84', 'ciUpperLimit': '-69.63', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.381', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-71.54', 'ciLowerLimit': '-92.34', 'ciUpperLimit': '-50.75', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.479', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-74.46', 'ciLowerLimit': '-95.59', 'ciUpperLimit': '-53.32', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.646', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-102.35', 'ciLowerLimit': '-123.49', 'ciUpperLimit': '-81.21', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.656', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-87.15', 'ciLowerLimit': '-107.76', 'ciUpperLimit': '-66.55', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.381', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '46.29', 'spread': '11.696', 'groupId': 'OG000'}, {'value': '47.75', 'spread': '10.864', 'groupId': 'OG001'}, {'value': '52.89', 'spread': '12.837', 'groupId': 'OG002'}, {'value': '49.23', 'spread': '14.621', 'groupId': 'OG003'}, {'value': '55.64', 'spread': '15.687', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.71', 'spread': '5.211', 'groupId': 'OG000'}, {'value': '0.18', 'spread': '5.052', 'groupId': 'OG001'}, {'value': '0.23', 'spread': '3.908', 'groupId': 'OG002'}, {'value': '-0.92', 'spread': '4.821', 'groupId': 'OG003'}, {'value': '0.00', 'spread': '5.349', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.13', 'spread': '5.050', 'groupId': 'OG000'}, {'value': '4.39', 'spread': '5.936', 'groupId': 'OG001'}, {'value': '2.23', 'spread': '3.930', 'groupId': 'OG002'}, {'value': '1.58', 'spread': '7.141', 'groupId': 'OG003'}, {'value': '2.21', 'spread': '6.830', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '4.354', 'groupId': 'OG000'}, {'value': '3.31', 'spread': '4.671', 'groupId': 'OG001'}, {'value': '2.54', 'spread': '6.280', 'groupId': 'OG002'}, {'value': '0.17', 'spread': '4.499', 'groupId': 'OG003'}, {'value': '4.79', 'spread': '7.122', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.46', 'spread': '7.149', 'groupId': 'OG000'}, {'value': '3.77', 'spread': '6.559', 'groupId': 'OG001'}, {'value': '2.46', 'spread': '7.304', 'groupId': 'OG002'}, {'value': '0.92', 'spread': '7.122', 'groupId': 'OG003'}, {'value': '5.36', 'spread': '4.483', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.29', 'spread': '6.315', 'groupId': 'OG000'}, {'value': '-1.31', 'spread': '10.355', 'groupId': 'OG001'}, {'value': '-1.46', 'spread': '4.832', 'groupId': 'OG002'}, {'value': '-0.25', 'spread': '5.586', 'groupId': 'OG003'}, {'value': '5.14', 'spread': '6.443', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.3064', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.01', 'ciLowerLimit': '-1.89', 'ciUpperLimit': '5.90', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.945', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1922', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.67', 'ciLowerLimit': '-1.38', 'ciUpperLimit': '6.73', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.025', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6827', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.82', 'ciLowerLimit': '-3.16', 'ciUpperLimit': '4.79', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.984', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2211', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.45', 'ciLowerLimit': '-1.52', 'ciUpperLimit': '6.42', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.981', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0033', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.64', 'ciLowerLimit': '2.31', 'ciUpperLimit': '10.97', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.158', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0269', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.09', 'ciLowerLimit': '0.60', 'ciUpperLimit': '9.57', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.237', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0890', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.87', 'ciLowerLimit': '-0.61', 'ciUpperLimit': '8.34', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.232', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0242', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.08', 'ciLowerLimit': '0.69', 'ciUpperLimit': '9.47', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.190', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1270', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.25', 'ciLowerLimit': '-0.95', 'ciUpperLimit': '7.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.101', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1199', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.40', 'ciLowerLimit': '-0.91', 'ciUpperLimit': '7.70', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.151', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.8123', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.51', 'ciLowerLimit': '-3.79', 'ciUpperLimit': '4.82', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.150', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0095', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.65', 'ciLowerLimit': '1.44', 'ciUpperLimit': '9.87', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.106', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1141', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.00', 'ciLowerLimit': '-0.99', 'ciUpperLimit': '8.99', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.492', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1552', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.65', 'ciLowerLimit': '-1.42', 'ciUpperLimit': '8.73', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.536', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5407', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.57', 'ciLowerLimit': '-3.53', 'ciUpperLimit': '6.67', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.547', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0107', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.56', 'ciLowerLimit': '1.58', 'ciUpperLimit': '11.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.485', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '191.46', 'spread': '20.999', 'groupId': 'OG000'}, {'value': '185.46', 'spread': '26.890', 'groupId': 'OG001'}, {'value': '186.46', 'spread': '29.171', 'groupId': 'OG002'}, {'value': '193.31', 'spread': '34.922', 'groupId': 'OG003'}, {'value': '191.57', 'spread': '26.355', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-6.96', 'spread': '10.212', 'groupId': 'OG000'}, {'value': '-61.46', 'spread': '17.091', 'groupId': 'OG001'}, {'value': '-52.19', 'spread': '16.982', 'groupId': 'OG002'}, {'value': '-76.23', 'spread': '27.030', 'groupId': 'OG003'}, {'value': '-71.50', 'spread': '29.506', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-9.21', 'spread': '21.912', 'groupId': 'OG000'}, {'value': '-81.82', 'spread': '22.163', 'groupId': 'OG001'}, {'value': '-73.19', 'spread': '31.471', 'groupId': 'OG002'}, {'value': '-99.25', 'spread': '34.162', 'groupId': 'OG003'}, {'value': '-97.00', 'spread': '25.070', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.46', 'spread': '24.362', 'groupId': 'OG000'}, {'value': '-88.31', 'spread': '20.754', 'groupId': 'OG001'}, {'value': '-92.35', 'spread': '21.685', 'groupId': 'OG002'}, {'value': '-112.25', 'spread': '35.962', 'groupId': 'OG003'}, {'value': '-104.93', 'spread': '28.080', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-14.21', 'spread': '13.327', 'groupId': 'OG000'}, {'value': '-87.23', 'spread': '19.842', 'groupId': 'OG001'}, {'value': '-90.81', 'spread': '25.136', 'groupId': 'OG002'}, {'value': '-117.67', 'spread': '45.816', 'groupId': 'OG003'}, {'value': '-109.50', 'spread': '28.156', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '22.738', 'groupId': 'OG000'}, {'value': '-10.08', 'spread': '28.522', 'groupId': 'OG001'}, {'value': '-10.42', 'spread': '19.339', 'groupId': 'OG002'}, {'value': '-16.17', 'spread': '33.701', 'groupId': 'OG003'}, {'value': '-68.79', 'spread': '43.324', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.35', 'ciLowerLimit': '-76.74', 'ciUpperLimit': '-43.97', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.152', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-52.53', 'ciLowerLimit': '-69.45', 'ciUpperLimit': '-35.61', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.422', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-69.46', 'ciLowerLimit': '-86.06', 'ciUpperLimit': '-52.86', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.260', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-66.25', 'ciLowerLimit': '-82.55', 'ciUpperLimit': '-49.94', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.112', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-78.46', 'ciLowerLimit': '-100.05', 'ciUpperLimit': '-56.87', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.766', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-71.28', 'ciLowerLimit': '-93.43', 'ciUpperLimit': '-49.13', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '11.051', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-91.83', 'ciLowerLimit': '-113.92', 'ciUpperLimit': '-69.74', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '11.018', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-89.50', 'ciLowerLimit': '-111.03', 'ciUpperLimit': '-67.97', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '10.736', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-86.73', 'ciLowerLimit': '-103.73', 'ciUpperLimit': '-69.72', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.452', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-92.18', 'ciLowerLimit': '-109.57', 'ciUpperLimit': '-74.80', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.643', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-106.06', 'ciLowerLimit': '-123.34', 'ciUpperLimit': '-88.78', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.585', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-99.18', 'ciLowerLimit': '-115.95', 'ciUpperLimit': '-82.40', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.334', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-79.07', 'ciLowerLimit': '-96.22', 'ciUpperLimit': '-61.93', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.557', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-83.89', 'ciLowerLimit': '-101.40', 'ciUpperLimit': '-66.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.736', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-104.74', 'ciLowerLimit': '-122.13', 'ciUpperLimit': '-87.35', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.679', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-97.00', 'ciLowerLimit': '-113.89', 'ciUpperLimit': '-80.11', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '8.426', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '152.92', 'spread': '52.761', 'groupId': 'OG000'}, {'value': '152.00', 'spread': '55.166', 'groupId': 'OG001'}, {'value': '130.36', 'spread': '41.199', 'groupId': 'OG002'}, {'value': '182.27', 'spread': '117.963', 'groupId': 'OG003'}, {'value': '137.96', 'spread': '70.799', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '4.33', 'spread': '53.163', 'groupId': 'OG000'}, {'value': '-12.21', 'spread': '52.707', 'groupId': 'OG001'}, {'value': '-15.69', 'spread': '41.689', 'groupId': 'OG002'}, {'value': '-32.35', 'spread': '52.814', 'groupId': 'OG003'}, {'value': '-2.18', 'spread': '66.044', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.92', 'spread': '47.001', 'groupId': 'OG000'}, {'value': '-19.00', 'spread': '32.268', 'groupId': 'OG001'}, {'value': '-13.92', 'spread': '44.051', 'groupId': 'OG002'}, {'value': '-23.54', 'spread': '40.176', 'groupId': 'OG003'}, {'value': '-16.32', 'spread': '32.999', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '7.75', 'spread': '39.352', 'groupId': 'OG000'}, {'value': '-17.62', 'spread': '45.629', 'groupId': 'OG001'}, {'value': '-3.54', 'spread': '39.199', 'groupId': 'OG002'}, {'value': '-45.29', 'spread': '82.959', 'groupId': 'OG003'}, {'value': '-13.75', 'spread': '47.976', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.00', 'spread': '43.389', 'groupId': 'OG000'}, {'value': '-24.23', 'spread': '36.103', 'groupId': 'OG001'}, {'value': '-14.38', 'spread': '53.705', 'groupId': 'OG002'}, {'value': '-60.21', 'spread': '102.224', 'groupId': 'OG003'}, {'value': '-26.25', 'spread': '29.632', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '52.33', 'spread': '177.350', 'groupId': 'OG000'}, {'value': '-1.77', 'spread': '52.488', 'groupId': 'OG001'}, {'value': '-1.00', 'spread': '35.576', 'groupId': 'OG002'}, {'value': '12.21', 'spread': '108.874', 'groupId': 'OG003'}, {'value': '-18.25', 'spread': '40.930', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.4480', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-22.30', 'ciLowerLimit': '-80.08', 'ciUpperLimit': '35.49', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.336', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2809', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.52', 'ciLowerLimit': '-91.80', 'ciUpperLimit': '26.76', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '30.091', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2875', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.92', 'ciLowerLimit': '-90.90', 'ciUpperLimit': '27.07', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.942', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5743', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.52', 'ciLowerLimit': '-74.38', 'ciUpperLimit': '41.33', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.370', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4997', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.83', 'ciLowerLimit': '-77.62', 'ciUpperLimit': '37.96', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.336', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4756', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.50', 'ciLowerLimit': '-80.78', 'ciUpperLimit': '37.78', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '30.091', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5610', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-17.73', 'ciLowerLimit': '-77.73', 'ciUpperLimit': '42.26', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '30.458', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4667', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.41', 'ciLowerLimit': '-79.27', 'ciUpperLimit': '36.44', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.370', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3045', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-30.70', 'ciLowerLimit': '-89.45', 'ciUpperLimit': '28.06', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.828', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4301', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.78', 'ciLowerLimit': '-83.06', 'ciUpperLimit': '35.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '30.091', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0881', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-52.15', 'ciLowerLimit': '-112.15', 'ciUpperLimit': '7.85', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '30.458', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2844', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.51', 'ciLowerLimit': '-89.36', 'ciUpperLimit': '26.35', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.370', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3741', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.56', 'ciLowerLimit': '-85.32', 'ciUpperLimit': '32.19', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.828', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4283', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.88', 'ciLowerLimit': '-83.16', 'ciUpperLimit': '35.40', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '30.091', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0657', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.32', 'ciLowerLimit': '-116.31', 'ciUpperLimit': '3.68', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '30.458', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2586', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.26', 'ciLowerLimit': '-91.11', 'ciUpperLimit': '24.60', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '29.370', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.15', 'spread': '10.895', 'groupId': 'OG000'}, {'value': '1.38', 'spread': '6.508', 'groupId': 'OG001'}, {'value': '0.55', 'spread': '8.065', 'groupId': 'OG002'}, {'value': '-1.17', 'spread': '7.549', 'groupId': 'OG003'}, {'value': '-0.19', 'spread': '9.462', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.18', 'spread': '10.362', 'groupId': 'OG000'}, {'value': '10.03', 'spread': '10.615', 'groupId': 'OG001'}, {'value': '5.67', 'spread': '8.409', 'groupId': 'OG002'}, {'value': '4.99', 'spread': '9.450', 'groupId': 'OG003'}, {'value': '6.11', 'spread': '14.252', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.38', 'spread': '8.315', 'groupId': 'OG000'}, {'value': '4.01', 'spread': '9.735', 'groupId': 'OG001'}, {'value': '1.90', 'spread': '10.085', 'groupId': 'OG002'}, {'value': '-1.61', 'spread': '6.994', 'groupId': 'OG003'}, {'value': '4.92', 'spread': '9.366', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.62', 'spread': '8.538', 'groupId': 'OG000'}, {'value': '5.82', 'spread': '8.244', 'groupId': 'OG001'}, {'value': '1.80', 'spread': '8.623', 'groupId': 'OG002'}, {'value': '1.20', 'spread': '7.435', 'groupId': 'OG003'}, {'value': '3.51', 'spread': '11.179', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-5.85', 'spread': '7.270', 'groupId': 'OG000'}, {'value': '-4.61', 'spread': '15.035', 'groupId': 'OG001'}, {'value': '-3.48', 'spread': '9.082', 'groupId': 'OG002'}, {'value': '-3.77', 'spread': '10.868', 'groupId': 'OG003'}, {'value': '3.20', 'spread': '11.505', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.3326', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.33', 'ciLowerLimit': '-3.49', 'ciUpperLimit': '10.14', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.404', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2967', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.69', 'ciLowerLimit': '-3.32', 'ciUpperLimit': '10.70', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.502', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.8812', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.52', 'ciLowerLimit': '-6.42', 'ciUpperLimit': '7.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.466', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3227', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.42', 'ciLowerLimit': '-3.45', 'ciUpperLimit': '10.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.433', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0210', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '10.01', 'ciLowerLimit': '1.56', 'ciUpperLimit': '18.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.221', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1192', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.84', 'ciLowerLimit': '-1.82', 'ciUpperLimit': '15.49', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.326', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2529', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.04', 'ciLowerLimit': '-3.69', 'ciUpperLimit': '13.78', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.367', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0725', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.76', 'ciLowerLimit': '-0.73', 'ciUpperLimit': '16.25', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.244', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0405', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.74', 'ciLowerLimit': '0.30', 'ciUpperLimit': '13.18', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.214', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0593', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.27', 'ciLowerLimit': '-0.25', 'ciUpperLimit': '12.80', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.258', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5936', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.76', 'ciLowerLimit': '-4.81', 'ciUpperLimit': '8.33', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.279', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0034', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.78', 'ciLowerLimit': '3.38', 'ciUpperLimit': '16.17', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.192', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0305', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.60', 'ciLowerLimit': '0.74', 'ciUpperLimit': '14.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.428', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1252', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.41', 'ciLowerLimit': '-1.55', 'ciUpperLimit': '12.37', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.479', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2923', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.71', 'ciLowerLimit': '-3.28', 'ciUpperLimit': '10.71', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.495', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0297', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.60', 'ciLowerLimit': '0.78', 'ciUpperLimit': '14.43', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.411', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline In Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-5.78', 'spread': '12.548', 'groupId': 'OG000'}, {'value': '-31.37', 'spread': '7.019', 'groupId': 'OG001'}, {'value': '-27.78', 'spread': '9.784', 'groupId': 'OG002'}, {'value': '-36.61', 'spread': '12.248', 'groupId': 'OG003'}, {'value': '-34.71', 'spread': '9.872', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.08', 'spread': '7.974', 'groupId': 'OG000'}, {'value': '-39.63', 'spread': '11.339', 'groupId': 'OG001'}, {'value': '-38.94', 'spread': '15.373', 'groupId': 'OG002'}, {'value': '-49.03', 'spread': '15.663', 'groupId': 'OG003'}, {'value': '-47.45', 'spread': '12.424', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-5.17', 'spread': '9.548', 'groupId': 'OG000'}, {'value': '-42.06', 'spread': '8.865', 'groupId': 'OG001'}, {'value': '-43.87', 'spread': '10.909', 'groupId': 'OG002'}, {'value': '-51.52', 'spread': '12.657', 'groupId': 'OG003'}, {'value': '-49.45', 'spread': '13.498', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-6.61', 'spread': '10.206', 'groupId': 'OG000'}, {'value': '-44.37', 'spread': '10.311', 'groupId': 'OG001'}, {'value': '-45.51', 'spread': '12.176', 'groupId': 'OG002'}, {'value': '-55.74', 'spread': '15.477', 'groupId': 'OG003'}, {'value': '-53.15', 'spread': '10.682', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-6.24', 'spread': '10.119', 'groupId': 'OG000'}, {'value': '-6.11', 'spread': '13.750', 'groupId': 'OG001'}, {'value': '-7.95', 'spread': '11.527', 'groupId': 'OG002'}, {'value': '-8.40', 'spread': '13.819', 'groupId': 'OG003'}, {'value': '-33.66', 'spread': '17.828', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.35', 'ciLowerLimit': '-34.59', 'ciUpperLimit': '-18.10', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.117', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-24.29', 'ciLowerLimit': '-32.95', 'ciUpperLimit': '-15.63', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.325', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.20', 'ciLowerLimit': '-39.58', 'ciUpperLimit': '-22.83', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.182', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-30.43', 'ciLowerLimit': '-38.78', 'ciUpperLimit': '-22.08', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.169', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.30', 'ciLowerLimit': '-43.42', 'ciUpperLimit': '-23.19', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.055', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.14', 'ciLowerLimit': '-44.65', 'ciUpperLimit': '-23.63', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.255', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-42.57', 'ciLowerLimit': '-52.96', 'ciUpperLimit': '-32.18', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.194', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.87', 'ciLowerLimit': '-52.07', 'ciUpperLimit': '-31.67', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.097', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.75', 'ciLowerLimit': '-46.46', 'ciUpperLimit': '-29.05', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.343', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-40.98', 'ciLowerLimit': '-50.04', 'ciUpperLimit': '-31.93', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.519', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.98', 'ciLowerLimit': '-55.88', 'ciUpperLimit': '-38.08', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.441', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-45.77', 'ciLowerLimit': '-54.52', 'ciUpperLimit': '-37.03', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.363', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.61', 'ciLowerLimit': '-47.85', 'ciUpperLimit': '-29.37', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.616', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.19', 'ciLowerLimit': '-50.78', 'ciUpperLimit': '-31.60', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.795', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.75', 'ciLowerLimit': '-59.20', 'ciUpperLimit': '-40.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.722', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-48.04', 'ciLowerLimit': '-57.33', 'ciUpperLimit': '-38.76', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.639', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline In Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.73', 'spread': '5.594', 'groupId': 'OG000'}, {'value': '-26.43', 'spread': '7.582', 'groupId': 'OG001'}, {'value': '-22.11', 'spread': '8.292', 'groupId': 'OG002'}, {'value': '-31.68', 'spread': '11.543', 'groupId': 'OG003'}, {'value': '-28.70', 'spread': '10.002', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.46', 'spread': '10.151', 'groupId': 'OG000'}, {'value': '-33.35', 'spread': '9.238', 'groupId': 'OG001'}, {'value': '-30.59', 'spread': '13.208', 'groupId': 'OG002'}, {'value': '-39.69', 'spread': '13.307', 'groupId': 'OG003'}, {'value': '-38.77', 'spread': '10.906', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.61', 'spread': '9.708', 'groupId': 'OG000'}, {'value': '-36.44', 'spread': '7.736', 'groupId': 'OG001'}, {'value': '-37.81', 'spread': '9.438', 'groupId': 'OG002'}, {'value': '-45.23', 'spread': '11.101', 'groupId': 'OG003'}, {'value': '-40.69', 'spread': '10.542', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-6.12', 'spread': '7.275', 'groupId': 'OG000'}, {'value': '-35.76', 'spread': '8.855', 'groupId': 'OG001'}, {'value': '-37.12', 'spread': '11.045', 'groupId': 'OG002'}, {'value': '-46.81', 'spread': '15.606', 'groupId': 'OG003'}, {'value': '-42.24', 'spread': '9.692', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.90', 'spread': '8.320', 'groupId': 'OG000'}, {'value': '-4.28', 'spread': '13.040', 'groupId': 'OG001'}, {'value': '-5.11', 'spread': '8.907', 'groupId': 'OG002'}, {'value': '-5.49', 'spread': '14.026', 'groupId': 'OG003'}, {'value': '-26.16', 'spread': '17.561', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-22.70', 'ciLowerLimit': '-31.06', 'ciUpperLimit': '-14.34', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.211', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.60', 'ciLowerLimit': '-27.17', 'ciUpperLimit': '-10.03', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.315', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-27.97', 'ciLowerLimit': '-36.46', 'ciUpperLimit': '-19.49', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.274', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-24.89', 'ciLowerLimit': '-33.24', 'ciUpperLimit': '-16.54', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.207', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.89', 'ciLowerLimit': '-37.25', 'ciUpperLimit': '-20.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.211', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.35', 'ciLowerLimit': '-34.92', 'ciUpperLimit': '-17.79', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.315', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.89', 'ciLowerLimit': '-44.46', 'ciUpperLimit': '-27.33', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.318', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.23', 'ciLowerLimit': '-42.58', 'ciUpperLimit': '-25.88', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.207', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.96', 'ciLowerLimit': '-42.39', 'ciUpperLimit': '-25.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.246', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.41', 'ciLowerLimit': '-43.98', 'ciUpperLimit': '-26.85', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.315', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.28', 'ciLowerLimit': '-51.85', 'ciUpperLimit': '-34.71', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.318', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.00', 'ciLowerLimit': '-46.35', 'ciUpperLimit': '-29.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.207', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.77', 'ciLowerLimit': '-38.19', 'ciUpperLimit': '-21.34', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.246', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.22', 'ciLowerLimit': '-39.79', 'ciUpperLimit': '-22.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.315', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.34', 'ciLowerLimit': '-49.91', 'ciUpperLimit': '-32.78', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.318', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-36.04', 'ciLowerLimit': '-44.39', 'ciUpperLimit': '-27.69', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.207', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline In Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.75', 'spread': '11.363', 'groupId': 'OG000'}, {'value': '1.26', 'spread': '10.469', 'groupId': 'OG001'}, {'value': '0.31', 'spread': '7.401', 'groupId': 'OG002'}, {'value': '-2.64', 'spread': '9.055', 'groupId': 'OG003'}, {'value': '0.61', 'spread': '10.217', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.98', 'spread': '10.134', 'groupId': 'OG000'}, {'value': '10.54', 'spread': '14.406', 'groupId': 'OG001'}, {'value': '4.72', 'spread': '8.025', 'groupId': 'OG002'}, {'value': '4.39', 'spread': '11.643', 'groupId': 'OG003'}, {'value': '5.56', 'spread': '13.089', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.48', 'spread': '9.693', 'groupId': 'OG000'}, {'value': '8.01', 'spread': '10.268', 'groupId': 'OG001'}, {'value': '5.49', 'spread': '11.126', 'groupId': 'OG002'}, {'value': '1.78', 'spread': '9.431', 'groupId': 'OG003'}, {'value': '9.83', 'spread': '14.119', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '14.389', 'groupId': 'OG000'}, {'value': '9.02', 'spread': '14.218', 'groupId': 'OG001'}, {'value': '4.55', 'spread': '12.030', 'groupId': 'OG002'}, {'value': '3.56', 'spread': '12.870', 'groupId': 'OG003'}, {'value': '11.44', 'spread': '10.270', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.40', 'spread': '13.662', 'groupId': 'OG000'}, {'value': '0.24', 'spread': '19.628', 'groupId': 'OG001'}, {'value': '-2.24', 'spread': '8.900', 'groupId': 'OG002'}, {'value': '-2.32', 'spread': '11.310', 'groupId': 'OG003'}, {'value': '11.35', 'spread': '13.124', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.2690', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.44', 'ciLowerLimit': '-3.53', 'ciUpperLimit': '12.41', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.975', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2122', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.22', 'ciLowerLimit': '-3.07', 'ciUpperLimit': '13.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.133', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.8953', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.54', 'ciLowerLimit': '-7.59', 'ciUpperLimit': '8.67', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.054', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1723', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.59', 'ciLowerLimit': '-2.51', 'ciUpperLimit': '13.70', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.045', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0010', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '14.95', 'ciLowerLimit': '6.34', 'ciUpperLimit': '23.56', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.293', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0179', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '10.86', 'ciLowerLimit': '1.95', 'ciUpperLimit': '19.78', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.451', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0462', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.06', 'ciLowerLimit': '0.16', 'ciUpperLimit': '17.96', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.440', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0091', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '11.78', 'ciLowerLimit': '3.05', 'ciUpperLimit': '20.52', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.358', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0774', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.31', 'ciLowerLimit': '-0.83', 'ciUpperLimit': '15.45', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.064', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0909', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.16', 'ciLowerLimit': '-1.18', 'ciUpperLimit': '15.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.165', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6107', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.13', 'ciLowerLimit': '-6.20', 'ciUpperLimit': '10.45', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.157', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0062', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '11.59', 'ciLowerLimit': '3.42', 'ciUpperLimit': '19.75', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.076', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0702', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.69', 'ciLowerLimit': '-0.74', 'ciUpperLimit': '18.13', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.712', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.1692', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.69', 'ciLowerLimit': '-2.93', 'ciUpperLimit': '16.32', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.807', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3751', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.31', 'ciLowerLimit': '-5.34', 'ciUpperLimit': '13.96', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.819', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.0053', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '13.65', 'ciLowerLimit': '4.23', 'ciUpperLimit': '23.08', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.709', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter.'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.85', 'spread': '5.557', 'groupId': 'OG000'}, {'value': '-33.32', 'spread': '8.161', 'groupId': 'OG001'}, {'value': '-28.56', 'spread': '8.868', 'groupId': 'OG002'}, {'value': '-39.11', 'spread': '12.195', 'groupId': 'OG003'}, {'value': '-36.85', 'spread': '11.918', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-4.33', 'spread': '11.789', 'groupId': 'OG000'}, {'value': '-44.54', 'spread': '12.261', 'groupId': 'OG001'}, {'value': '-40.54', 'spread': '15.915', 'groupId': 'OG002'}, {'value': '-50.81', 'spread': '14.320', 'groupId': 'OG003'}, {'value': '-50.85', 'spread': '12.789', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.27', 'spread': '12.091', 'groupId': 'OG000'}, {'value': '-47.43', 'spread': '7.666', 'groupId': 'OG001'}, {'value': '-50.15', 'spread': '10.327', 'groupId': 'OG002'}, {'value': '-57.08', 'spread': '10.801', 'groupId': 'OG003'}, {'value': '-54.61', 'spread': '11.948', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.45', 'spread': '7.261', 'groupId': 'OG000'}, {'value': '-46.96', 'spread': '8.425', 'groupId': 'OG001'}, {'value': '-49.29', 'spread': '12.890', 'groupId': 'OG002'}, {'value': '-59.12', 'spread': '15.643', 'groupId': 'OG003'}, {'value': '-56.98', 'spread': '10.994', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '11.797', 'groupId': 'OG000'}, {'value': '-4.84', 'spread': '14.681', 'groupId': 'OG001'}, {'value': '-5.97', 'spread': '10.711', 'groupId': 'OG002'}, {'value': '-6.62', 'spread': '16.960', 'groupId': 'OG003'}, {'value': '-36.83', 'spread': '24.401', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-30.64', 'ciLowerLimit': '-38.56', 'ciUpperLimit': '-22.72', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.951', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.62', 'ciLowerLimit': '-34.80', 'ciUpperLimit': '-18.44', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.084', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.27', 'ciLowerLimit': '-43.29', 'ciUpperLimit': '-27.24', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.003', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.42', 'ciLowerLimit': '-41.30', 'ciUpperLimit': '-25.54', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.931', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.38', 'ciLowerLimit': '-52.34', 'ciUpperLimit': '-30.42', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.467', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.12', 'ciLowerLimit': '-49.36', 'ciUpperLimit': '-26.88', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.610', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.42', 'ciLowerLimit': '-58.64', 'ciUpperLimit': '-36.20', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.599', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.93', 'ciLowerLimit': '-57.87', 'ciUpperLimit': '-36.00', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.453', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-45.37', 'ciLowerLimit': '-53.96', 'ciUpperLimit': '-36.77', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.275', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-48.78', 'ciLowerLimit': '-57.58', 'ciUpperLimit': '-39.99', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.374', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.49', 'ciLowerLimit': '-63.23', 'ciUpperLimit': '-45.75', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.346', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-51.75', 'ciLowerLimit': '-60.25', 'ciUpperLimit': '-43.26', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.222', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-40.82', 'ciLowerLimit': '-49.58', 'ciUpperLimit': '-32.07', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.373', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.75', 'ciLowerLimit': '-52.68', 'ciUpperLimit': '-34.81', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.464', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-52.36', 'ciLowerLimit': '-61.25', 'ciUpperLimit': '-43.48', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.437', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.94', 'ciLowerLimit': '-58.58', 'ciUpperLimit': '-41.31', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.312', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.25', 'spread': '30.696', 'groupId': 'OG000'}, {'value': '0.47', 'spread': '36.664', 'groupId': 'OG001'}, {'value': '-9.47', 'spread': '33.634', 'groupId': 'OG002'}, {'value': '-15.52', 'spread': '25.106', 'groupId': 'OG003'}, {'value': '-1.90', 'spread': '35.794', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.76', 'spread': '38.074', 'groupId': 'OG000'}, {'value': '-9.97', 'spread': '19.639', 'groupId': 'OG001'}, {'value': '-8.88', 'spread': '29.664', 'groupId': 'OG002'}, {'value': '-8.87', 'spread': '16.916', 'groupId': 'OG003'}, {'value': '-8.36', 'spread': '32.603', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.29', 'spread': '25.939', 'groupId': 'OG000'}, {'value': '-9.14', 'spread': '24.192', 'groupId': 'OG001'}, {'value': '-2.82', 'spread': '31.720', 'groupId': 'OG002'}, {'value': '-13.00', 'spread': '28.724', 'groupId': 'OG003'}, {'value': '-8.11', 'spread': '31.027', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 29', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-6.35', 'spread': '24.168', 'groupId': 'OG000'}, {'value': '-15.68', 'spread': '17.890', 'groupId': 'OG001'}, {'value': '-13.18', 'spread': '39.826', 'groupId': 'OG002'}, {'value': '-19.81', 'spread': '34.900', 'groupId': 'OG003'}, {'value': '-18.32', 'spread': '21.062', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '35.06', 'spread': '123.074', 'groupId': 'OG000'}, {'value': '4.27', 'spread': '33.925', 'groupId': 'OG001'}, {'value': '-2.18', 'spread': '32.081', 'groupId': 'OG002'}, {'value': '4.74', 'spread': '43.369', 'groupId': 'OG003'}, {'value': '-12.42', 'spread': '28.128', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '0.9789', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.52', 'ciLowerLimit': '-39.08', 'ciUpperLimit': '38.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.581', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5525', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-11.94', 'ciLowerLimit': '-51.46', 'ciUpperLimit': '27.59', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '20.069', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5035', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-13.39', 'ciLowerLimit': '-52.73', 'ciUpperLimit': '25.96', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.979', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.8302', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.21', 'ciLowerLimit': '-42.81', 'ciUpperLimit': '34.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.601', 'groupDescription': 'Day 8: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5590', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-11.45', 'ciLowerLimit': '-50.01', 'ciUpperLimit': '27.10', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.581', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5558', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-11.84', 'ciLowerLimit': '-51.36', 'ciUpperLimit': '27.69', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '20.069', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.6835', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-8.30', 'ciLowerLimit': '-48.34', 'ciUpperLimit': '31.74', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '20.332', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5699', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-11.15', 'ciLowerLimit': '-49.75', 'ciUpperLimit': '27.45', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.601', 'groupDescription': 'Day 15: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3826', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-17.42', 'ciLowerLimit': '-56.64', 'ciUpperLimit': '21.80', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.918', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5233', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-12.83', 'ciLowerLimit': '-52.35', 'ciUpperLimit': '26.70', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '20.069', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3391', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.47', 'ciLowerLimit': '-59.51', 'ciUpperLimit': '20.57', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '20.332', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3606', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-17.95', 'ciLowerLimit': '-56.55', 'ciUpperLimit': '20.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.601', 'groupDescription': 'Day 22: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5364', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-12.33', 'ciLowerLimit': '-51.55', 'ciUpperLimit': '26.89', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.918', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.5651', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-11.56', 'ciLowerLimit': '-51.08', 'ciUpperLimit': '27.96', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '20.069', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.4719', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-14.65', 'ciLowerLimit': '-54.69', 'ciUpperLimit': '25.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '20.332', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.3999', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.53', 'ciLowerLimit': '-55.13', 'ciUpperLimit': '22.07', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '19.601', 'groupDescription': 'Day 29: Analysis was performed using the ANCOVA treatment, screening LDL-C stratum, study day, treatment-by-LDL-C stratum, and study day by treatment interaction as fixed effects, baseline as a covariate and participant as a random effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 29 and 78', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline In Low Density Lipoprotein Cholesterol (LDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '20.37', 'spread': '0.713', 'groupId': 'OG000'}, {'value': '20.48', 'spread': '0.833', 'groupId': 'OG001'}, {'value': '21.04', 'spread': '1.059', 'groupId': 'OG002'}, {'value': '20.66', 'spread': '1.018', 'groupId': 'OG003'}, {'value': '21.18', 'spread': '1.132', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.600', 'groupId': 'OG000'}, {'value': '0.07', 'spread': '0.334', 'groupId': 'OG001'}, {'value': '0.06', 'spread': '0.399', 'groupId': 'OG002'}, {'value': '-0.02', 'spread': '0.446', 'groupId': 'OG003'}, {'value': '0.09', 'spread': '0.380', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.23', 'spread': '0.661', 'groupId': 'OG000'}, {'value': '-0.13', 'spread': '0.403', 'groupId': 'OG001'}, {'value': '0.19', 'spread': '0.463', 'groupId': 'OG002'}, {'value': '-0.08', 'spread': '0.496', 'groupId': 'OG003'}, {'value': '0.05', 'spread': '0.372', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.403', 'groupId': 'OG000'}, {'value': '0.24', 'spread': '0.333', 'groupId': 'OG001'}, {'value': '0.10', 'spread': '0.567', 'groupId': 'OG002'}, {'value': '0.08', 'spread': '0.564', 'groupId': 'OG003'}, {'value': '0.08', 'spread': '0.507', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.382', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.352', 'groupId': 'OG001'}, {'value': '0.22', 'spread': '0.518', 'groupId': 'OG002'}, {'value': '0.07', 'spread': '0.509', 'groupId': 'OG003'}, {'value': '0.09', 'spread': '0.766', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.487', 'groupId': 'OG000'}, {'value': '-0.08', 'spread': '0.285', 'groupId': 'OG001'}, {'value': '-0.18', 'spread': '0.463', 'groupId': 'OG002'}, {'value': '-0.02', 'spread': '0.327', 'groupId': 'OG003'}, {'value': '0.11', 'spread': '0.595', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.19', 'spread': '0.601', 'groupId': 'OG000'}, {'value': '-0.19', 'spread': '0.413', 'groupId': 'OG001'}, {'value': '-0.18', 'spread': '0.426', 'groupId': 'OG002'}, {'value': '-0.08', 'spread': '0.379', 'groupId': 'OG003'}, {'value': '0.04', 'spread': '0.497', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.367', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.551', 'groupId': 'OG001'}, {'value': '-0.15', 'spread': '0.533', 'groupId': 'OG002'}, {'value': '-0.09', 'spread': '0.323', 'groupId': 'OG003'}, {'value': '0.08', 'spread': '0.435', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nanometer (nm)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline In Small Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1436.42', 'spread': '476.114', 'groupId': 'OG000'}, {'value': '1285.21', 'spread': '510.295', 'groupId': 'OG001'}, {'value': '982.14', 'spread': '660.248', 'groupId': 'OG002'}, {'value': '1163.69', 'spread': '625.676', 'groupId': 'OG003'}, {'value': '870.07', 'spread': '564.004', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-104.67', 'spread': '421.388', 'groupId': 'OG000'}, {'value': '-435.86', 'spread': '323.733', 'groupId': 'OG001'}, {'value': '-304.85', 'spread': '390.365', 'groupId': 'OG002'}, {'value': '-459.31', 'spread': '379.905', 'groupId': 'OG003'}, {'value': '-321.71', 'spread': '311.160', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-21.08', 'spread': '348.697', 'groupId': 'OG000'}, {'value': '-521.15', 'spread': '397.925', 'groupId': 'OG001'}, {'value': '-450.31', 'spread': '458.385', 'groupId': 'OG002'}, {'value': '-567.67', 'spread': '533.371', 'groupId': 'OG003'}, {'value': '-470.93', 'spread': '348.889', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-62.92', 'spread': '369.272', 'groupId': 'OG000'}, {'value': '-665.23', 'spread': '392.357', 'groupId': 'OG001'}, {'value': '-450.85', 'spread': '531.247', 'groupId': 'OG002'}, {'value': '-696.42', 'spread': '589.692', 'groupId': 'OG003'}, {'value': '-513.07', 'spread': '392.796', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-58.92', 'spread': '273.321', 'groupId': 'OG000'}, {'value': '-245.77', 'spread': '326.908', 'groupId': 'OG001'}, {'value': '-534.62', 'spread': '480.776', 'groupId': 'OG002'}, {'value': '-697.50', 'spread': '565.896', 'groupId': 'OG003'}, {'value': '-540.93', 'spread': '394.389', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '38.58', 'spread': '341.805', 'groupId': 'OG000'}, {'value': '19.31', 'spread': '136.299', 'groupId': 'OG001'}, {'value': '-88.15', 'spread': '311.715', 'groupId': 'OG002'}, {'value': '-450.17', 'spread': '475.951', 'groupId': 'OG003'}, {'value': '-514.64', 'spread': '444.216', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '35.58', 'spread': '410.428', 'groupId': 'OG000'}, {'value': '102.15', 'spread': '222.450', 'groupId': 'OG001'}, {'value': '60.00', 'spread': '245.038', 'groupId': 'OG002'}, {'value': '-165.33', 'spread': '302.403', 'groupId': 'OG003'}, {'value': '-441.29', 'spread': '420.139', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-17.25', 'spread': '256.900', 'groupId': 'OG000'}, {'value': '-70.92', 'spread': '356.896', 'groupId': 'OG001'}, {'value': '39.00', 'spread': '417.482', 'groupId': 'OG002'}, {'value': '-57.33', 'spread': '364.799', 'groupId': 'OG003'}, {'value': '-299.43', 'spread': '315.715', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nanomoles per liter (nmol/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline In Medium Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '302.67', 'spread': '103.271', 'groupId': 'OG000'}, {'value': '257.57', 'spread': '98.358', 'groupId': 'OG001'}, {'value': '196.57', 'spread': '128.296', 'groupId': 'OG002'}, {'value': '237.31', 'spread': '135.958', 'groupId': 'OG003'}, {'value': '171.14', 'spread': '114.370', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-45.33', 'spread': '77.296', 'groupId': 'OG000'}, {'value': '-70.71', 'spread': '66.675', 'groupId': 'OG001'}, {'value': '-52.77', 'spread': '77.953', 'groupId': 'OG002'}, {'value': '-89.62', 'spread': '96.271', 'groupId': 'OG003'}, {'value': '-58.00', 'spread': '69.471', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-17.92', 'spread': '90.062', 'groupId': 'OG000'}, {'value': '-88.15', 'spread': '85.983', 'groupId': 'OG001'}, {'value': '-83.85', 'spread': '91.519', 'groupId': 'OG002'}, {'value': '-105.25', 'spread': '124.532', 'groupId': 'OG003'}, {'value': '-83.29', 'spread': '70.268', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-17.33', 'spread': '72.118', 'groupId': 'OG000'}, {'value': '-113.54', 'spread': '84.567', 'groupId': 'OG001'}, {'value': '-77.54', 'spread': '104.141', 'groupId': 'OG002'}, {'value': '-126.50', 'spread': '134.014', 'groupId': 'OG003'}, {'value': '-95.93', 'spread': '80.612', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-26.58', 'spread': '70.370', 'groupId': 'OG000'}, {'value': '-39.85', 'spread': '75.660', 'groupId': 'OG001'}, {'value': '-103.46', 'spread': '96.958', 'groupId': 'OG002'}, {'value': '-128.83', 'spread': '128.898', 'groupId': 'OG003'}, {'value': '-95.93', 'spread': '75.083', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.42', 'spread': '67.594', 'groupId': 'OG000'}, {'value': '16.77', 'spread': '46.490', 'groupId': 'OG001'}, {'value': '-1.23', 'spread': '63.816', 'groupId': 'OG002'}, {'value': '-76.00', 'spread': '105.963', 'groupId': 'OG003'}, {'value': '-89.57', 'spread': '89.102', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-7.50', 'spread': '91.363', 'groupId': 'OG000'}, {'value': '32.69', 'spread': '52.454', 'groupId': 'OG001'}, {'value': '16.08', 'spread': '54.920', 'groupId': 'OG002'}, {'value': '-18.75', 'spread': '63.438', 'groupId': 'OG003'}, {'value': '-75.14', 'spread': '84.820', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-12.25', 'spread': '53.177', 'groupId': 'OG000'}, {'value': '-2.69', 'spread': '76.234', 'groupId': 'OG001'}, {'value': '18.23', 'spread': '84.810', 'groupId': 'OG002'}, {'value': '-5.08', 'spread': '77.809', 'groupId': 'OG003'}, {'value': '-54.79', 'spread': '59.832', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline In Large Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '367.42', 'spread': '251.928', 'groupId': 'OG000'}, {'value': '424.71', 'spread': '336.502', 'groupId': 'OG001'}, {'value': '578.57', 'spread': '346.792', 'groupId': 'OG002'}, {'value': '459.00', 'spread': '341.699', 'groupId': 'OG003'}, {'value': '639.36', 'spread': '378.728', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '16.42', 'spread': '238.022', 'groupId': 'OG000'}, {'value': '-135.36', 'spread': '140.673', 'groupId': 'OG001'}, {'value': '-138.69', 'spread': '108.767', 'groupId': 'OG002'}, {'value': '-163.85', 'spread': '183.861', 'groupId': 'OG003'}, {'value': '-219.64', 'spread': '173.835', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-71.67', 'spread': '265.452', 'groupId': 'OG000'}, {'value': '-198.31', 'spread': '154.965', 'groupId': 'OG001'}, {'value': '-173.08', 'spread': '158.586', 'groupId': 'OG002'}, {'value': '-248.25', 'spread': '218.091', 'groupId': 'OG003'}, {'value': '-297.36', 'spread': '201.235', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-26.50', 'spread': '137.911', 'groupId': 'OG000'}, {'value': '-162.69', 'spread': '170.876', 'groupId': 'OG001'}, {'value': '-237.00', 'spread': '173.930', 'groupId': 'OG002'}, {'value': '-271.58', 'spread': '219.097', 'groupId': 'OG003'}, {'value': '-311.36', 'spread': '215.078', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-38.17', 'spread': '164.092', 'groupId': 'OG000'}, {'value': '-93.15', 'spread': '170.770', 'groupId': 'OG001'}, {'value': '-236.23', 'spread': '180.758', 'groupId': 'OG002'}, {'value': '-244.75', 'spread': '219.917', 'groupId': 'OG003'}, {'value': '-333.64', 'spread': '266.184', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '18.83', 'spread': '159.906', 'groupId': 'OG000'}, {'value': '-70.38', 'spread': '111.722', 'groupId': 'OG001'}, {'value': '-177.46', 'spread': '177.244', 'groupId': 'OG002'}, {'value': '-226.75', 'spread': '161.785', 'groupId': 'OG003'}, {'value': '-337.00', 'spread': '215.720', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-45.08', 'spread': '227.314', 'groupId': 'OG000'}, {'value': '-114.31', 'spread': '208.922', 'groupId': 'OG001'}, {'value': '-79.69', 'spread': '168.660', 'groupId': 'OG002'}, {'value': '-147.75', 'spread': '155.138', 'groupId': 'OG003'}, {'value': '-341.57', 'spread': '243.742', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-50.08', 'spread': '133.655', 'groupId': 'OG000'}, {'value': '-31.23', 'spread': '254.307', 'groupId': 'OG001'}, {'value': '-108.15', 'spread': '159.176', 'groupId': 'OG002'}, {'value': '-85.25', 'spread': '91.821', 'groupId': 'OG003'}, {'value': '-215.43', 'spread': '230.488', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Change From Baseline In Total Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1898.83', 'spread': '393.934', 'groupId': 'OG000'}, {'value': '1789.29', 'spread': '297.035', 'groupId': 'OG001'}, {'value': '1626.14', 'spread': '474.106', 'groupId': 'OG002'}, {'value': '1694.15', 'spread': '439.012', 'groupId': 'OG003'}, {'value': '1549.71', 'spread': '332.241', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-100.42', 'spread': '326.272', 'groupId': 'OG000'}, {'value': '-598.00', 'spread': '253.302', 'groupId': 'OG001'}, {'value': '-460.08', 'spread': '351.468', 'groupId': 'OG002'}, {'value': '-664.00', 'spread': '332.371', 'groupId': 'OG003'}, {'value': '-557.86', 'spread': '245.049', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-87.67', 'spread': '269.313', 'groupId': 'OG000'}, {'value': '-756.46', 'spread': '300.314', 'groupId': 'OG001'}, {'value': '-658.08', 'spread': '400.172', 'groupId': 'OG002'}, {'value': '-851.67', 'spread': '447.423', 'groupId': 'OG003'}, {'value': '-790.14', 'spread': '269.961', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-89.17', 'spread': '344.100', 'groupId': 'OG000'}, {'value': '-877.62', 'spread': '276.218', 'groupId': 'OG001'}, {'value': '-735.92', 'spread': '462.348', 'groupId': 'OG002'}, {'value': '-1015.00', 'spread': '482.252', 'groupId': 'OG003'}, {'value': '-846.71', 'spread': '303.019', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-113.58', 'spread': '299.598', 'groupId': 'OG000'}, {'value': '-345.46', 'spread': '272.208', 'groupId': 'OG001'}, {'value': '-805.46', 'spread': '413.417', 'groupId': 'OG002'}, {'value': '-986.75', 'spread': '466.474', 'groupId': 'OG003'}, {'value': '-894.21', 'spread': '284.814', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '63.00', 'spread': '303.420', 'groupId': 'OG000'}, {'value': '-45.23', 'spread': '128.264', 'groupId': 'OG001'}, {'value': '-278.23', 'spread': '268.441', 'groupId': 'OG002'}, {'value': '-705.00', 'spread': '486.227', 'groupId': 'OG003'}, {'value': '-879.50', 'spread': '322.993', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.33', 'spread': '287.226', 'groupId': 'OG000'}, {'value': '10.62', 'spread': '191.872', 'groupId': 'OG001'}, {'value': '-14.77', 'spread': '231.884', 'groupId': 'OG002'}, {'value': '-309.25', 'spread': '396.535', 'groupId': 'OG003'}, {'value': '-801.36', 'spread': '354.429', 'groupId': 'OG004'}]}]}, {'title': 'Change at Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-60.83', 'spread': '285.233', 'groupId': 'OG000'}, {'value': '-105.62', 'spread': '319.186', 'groupId': 'OG001'}, {'value': '-72.69', 'spread': '364.420', 'groupId': 'OG002'}, {'value': '-143.42', 'spread': '432.459', 'groupId': 'OG003'}, {'value': '-529.57', 'spread': '294.496', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Levels at Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '48.83', 'spread': '22.741', 'groupId': 'OG000'}, {'value': '43.96', 'spread': '23.731', 'groupId': 'OG001'}, {'value': '43.07', 'spread': '23.580', 'groupId': 'OG002'}, {'value': '34.10', 'spread': '20.316', 'groupId': 'OG003'}, {'value': '44.12', 'spread': '24.425', 'groupId': 'OG004'}]}]}, {'title': 'Day 8', 'categories': [{'measurements': [{'value': '48.53', 'spread': '21.549', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'categories': [{'measurements': [{'value': '50.42', 'spread': '22.170', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '52.58', 'spread': '29.516', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'categories': [{'measurements': [{'value': '51.80', 'spread': '24.231', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'categories': [{'measurements': [{'value': '48.21', 'spread': '19.973', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'categories': [{'measurements': [{'value': '51.95', 'spread': '25.584', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'categories': [{'measurements': [{'value': '43.75', 'spread': '23.686', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data could not be evaluated since the value was below Lower Limit of Quantification (LLQ).', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacodynamic analysis population was defined as all enrolled participants who received at least 1 dose of study medication and had atleast 1 pharmacodynamic parameter.'}, {'type': 'SECONDARY', 'title': 'C-Reactive Protein Levels at Day 8, 15, 21, 36, 57 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.23', 'spread': '0.252', 'groupId': 'OG000'}, {'value': '0.26', 'spread': '0.204', 'groupId': 'OG001'}, {'value': '0.18', 'spread': '0.251', 'groupId': 'OG002'}, {'value': '0.42', 'spread': '0.506', 'groupId': 'OG003'}, {'value': '0.16', 'spread': '0.191', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.30', 'spread': '0.385', 'groupId': 'OG000'}, {'value': '0.23', 'spread': '0.206', 'groupId': 'OG001'}, {'value': '0.25', 'spread': '0.433', 'groupId': 'OG002'}, {'value': '0.38', 'spread': '0.553', 'groupId': 'OG003'}, {'value': '0.20', 'spread': '0.293', 'groupId': 'OG004'}]}]}, {'title': 'Day 21', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.27', 'spread': '0.320', 'groupId': 'OG000'}, {'value': '0.23', 'spread': '0.194', 'groupId': 'OG001'}, {'value': '0.23', 'spread': '0.441', 'groupId': 'OG002'}, {'value': '0.32', 'spread': '0.464', 'groupId': 'OG003'}, {'value': '0.21', 'spread': '0.364', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.34', 'spread': '0.407', 'groupId': 'OG000'}, {'value': '0.27', 'spread': '0.255', 'groupId': 'OG001'}, {'value': '0.27', 'spread': '0.450', 'groupId': 'OG002'}, {'value': '0.28', 'spread': '0.306', 'groupId': 'OG003'}, {'value': '0.26', 'spread': '0.541', 'groupId': 'OG004'}]}]}, {'title': 'Day 57', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.21', 'spread': '0.205', 'groupId': 'OG000'}, {'value': '0.36', 'spread': '0.502', 'groupId': 'OG001'}, {'value': '0.21', 'spread': '0.368', 'groupId': 'OG002'}, {'value': '0.51', 'spread': '0.985', 'groupId': 'OG003'}, {'value': '0.18', 'spread': '0.220', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.32', 'spread': '0.400', 'groupId': 'OG000'}, {'value': '0.33', 'spread': '0.522', 'groupId': 'OG001'}, {'value': '0.21', 'spread': '0.291', 'groupId': 'OG002'}, {'value': '0.54', 'spread': '1.175', 'groupId': 'OG003'}, {'value': '0.15', 'spread': '0.141', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 21, 36, 57 and 78', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had atleast 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Small High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '23.26', 'spread': '3.147', 'groupId': 'OG000'}, {'value': '22.79', 'spread': '3.210', 'groupId': 'OG001'}, {'value': '20.64', 'spread': '7.390', 'groupId': 'OG002'}, {'value': '19.74', 'spread': '5.807', 'groupId': 'OG003'}, {'value': '21.49', 'spread': '5.767', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '23.13', 'spread': '5.511', 'groupId': 'OG000'}, {'value': '24.04', 'spread': '3.831', 'groupId': 'OG001'}, {'value': '22.39', 'spread': '6.412', 'groupId': 'OG002'}, {'value': '19.04', 'spread': '5.768', 'groupId': 'OG003'}, {'value': '21.87', 'spread': '7.229', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '22.74', 'spread': '5.162', 'groupId': 'OG000'}, {'value': '23.67', 'spread': '4.626', 'groupId': 'OG001'}, {'value': '21.60', 'spread': '6.865', 'groupId': 'OG002'}, {'value': '21.57', 'spread': '6.763', 'groupId': 'OG003'}, {'value': '21.02', 'spread': '6.531', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '23.16', 'spread': '5.582', 'groupId': 'OG000'}, {'value': '23.33', 'spread': '5.223', 'groupId': 'OG001'}, {'value': '21.72', 'spread': '5.804', 'groupId': 'OG002'}, {'value': '19.18', 'spread': '6.676', 'groupId': 'OG003'}, {'value': '22.59', 'spread': '5.060', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '23.25', 'spread': '3.395', 'groupId': 'OG000'}, {'value': '23.73', 'spread': '4.924', 'groupId': 'OG001'}, {'value': '23.37', 'spread': '5.005', 'groupId': 'OG002'}, {'value': '22.83', 'spread': '6.103', 'groupId': 'OG003'}, {'value': '22.61', 'spread': '8.649', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '25.13', 'spread': '4.747', 'groupId': 'OG000'}, {'value': '23.02', 'spread': '6.617', 'groupId': 'OG001'}, {'value': '22.89', 'spread': '5.298', 'groupId': 'OG002'}, {'value': '20.73', 'spread': '5.579', 'groupId': 'OG003'}, {'value': '22.92', 'spread': '7.777', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '22.79', 'spread': '4.176', 'groupId': 'OG000'}, {'value': '22.25', 'spread': '6.245', 'groupId': 'OG001'}, {'value': '21.85', 'spread': '5.610', 'groupId': 'OG002'}, {'value': '20.16', 'spread': '5.633', 'groupId': 'OG003'}, {'value': '21.11', 'spread': '6.976', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'micromole/liter (umol/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had atleast 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Medium High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '1.90', 'spread': '2.158', 'groupId': 'OG000'}, {'value': '4.24', 'spread': '3.086', 'groupId': 'OG001'}, {'value': '5.12', 'spread': '3.778', 'groupId': 'OG002'}, {'value': '6.24', 'spread': '4.067', 'groupId': 'OG003'}, {'value': '5.29', 'spread': '5.057', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '2.80', 'spread': '2.888', 'groupId': 'OG000'}, {'value': '4.88', 'spread': '2.467', 'groupId': 'OG001'}, {'value': '4.82', 'spread': '3.408', 'groupId': 'OG002'}, {'value': '8.69', 'spread': '5.054', 'groupId': 'OG003'}, {'value': '5.84', 'spread': '6.642', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '3.26', 'spread': '2.394', 'groupId': 'OG000'}, {'value': '5.60', 'spread': '3.836', 'groupId': 'OG001'}, {'value': '6.81', 'spread': '5.102', 'groupId': 'OG002'}, {'value': '5.71', 'spread': '3.563', 'groupId': 'OG003'}, {'value': '7.08', 'spread': '6.606', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '4.29', 'spread': '3.516', 'groupId': 'OG000'}, {'value': '4.75', 'spread': '3.583', 'groupId': 'OG001'}, {'value': '5.31', 'spread': '3.738', 'groupId': 'OG002'}, {'value': '8.34', 'spread': '6.035', 'groupId': 'OG003'}, {'value': '6.06', 'spread': '4.500', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '3.68', 'spread': '3.615', 'groupId': 'OG000'}, {'value': '3.48', 'spread': '2.869', 'groupId': 'OG001'}, {'value': '3.28', 'spread': '3.059', 'groupId': 'OG002'}, {'value': '4.94', 'spread': '3.596', 'groupId': 'OG003'}, {'value': '7.50', 'spread': '7.664', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '3.50', 'spread': '3.254', 'groupId': 'OG000'}, {'value': '2.82', 'spread': '2.722', 'groupId': 'OG001'}, {'value': '3.74', 'spread': '3.358', 'groupId': 'OG002'}, {'value': '4.73', 'spread': '3.772', 'groupId': 'OG003'}, {'value': '7.04', 'spread': '6.034', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '3.65', 'spread': '3.592', 'groupId': 'OG000'}, {'value': '3.28', 'spread': '3.006', 'groupId': 'OG001'}, {'value': '2.88', 'spread': '3.098', 'groupId': 'OG002'}, {'value': '4.19', 'spread': '4.274', 'groupId': 'OG003'}, {'value': '5.37', 'spread': '6.117', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Large High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.88', 'spread': '3.636', 'groupId': 'OG000'}, {'value': '6.81', 'spread': '3.963', 'groupId': 'OG001'}, {'value': '7.97', 'spread': '3.491', 'groupId': 'OG002'}, {'value': '6.87', 'spread': '4.608', 'groupId': 'OG003'}, {'value': '8.08', 'spread': '4.144', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.90', 'spread': '3.514', 'groupId': 'OG000'}, {'value': '6.11', 'spread': '3.684', 'groupId': 'OG001'}, {'value': '9.05', 'spread': '3.604', 'groupId': 'OG002'}, {'value': '7.03', 'spread': '3.833', 'groupId': 'OG003'}, {'value': '8.36', 'spread': '3.815', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '6.23', 'spread': '3.497', 'groupId': 'OG000'}, {'value': '6.85', 'spread': '3.152', 'groupId': 'OG001'}, {'value': '7.93', 'spread': '3.943', 'groupId': 'OG002'}, {'value': '6.75', 'spread': '3.544', 'groupId': 'OG003'}, {'value': '8.88', 'spread': '4.919', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.70', 'spread': '2.763', 'groupId': 'OG000'}, {'value': '6.97', 'spread': '4.091', 'groupId': 'OG001'}, {'value': '8.25', 'spread': '4.123', 'groupId': 'OG002'}, {'value': '7.74', 'spread': '4.124', 'groupId': 'OG003'}, {'value': '8.94', 'spread': '3.656', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.95', 'spread': '3.293', 'groupId': 'OG000'}, {'value': '5.98', 'spread': '3.452', 'groupId': 'OG001'}, {'value': '7.58', 'spread': '4.065', 'groupId': 'OG002'}, {'value': '7.90', 'spread': '4.608', 'groupId': 'OG003'}, {'value': '9.06', 'spread': '4.073', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.78', 'spread': '3.155', 'groupId': 'OG000'}, {'value': '5.98', 'spread': '2.471', 'groupId': 'OG001'}, {'value': '7.47', 'spread': '3.564', 'groupId': 'OG002'}, {'value': '7.41', 'spread': '5.359', 'groupId': 'OG003'}, {'value': '7.65', 'spread': '2.848', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.17', 'spread': '2.934', 'groupId': 'OG000'}, {'value': '5.61', 'spread': '2.271', 'groupId': 'OG001'}, {'value': '7.74', 'spread': '3.788', 'groupId': 'OG002'}, {'value': '7.16', 'spread': '4.958', 'groupId': 'OG003'}, {'value': '8.56', 'spread': '3.747', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Total High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '31.07', 'spread': '5.339', 'groupId': 'OG000'}, {'value': '33.84', 'spread': '4.326', 'groupId': 'OG001'}, {'value': '33.72', 'spread': '5.344', 'groupId': 'OG002'}, {'value': '32.85', 'spread': '7.554', 'groupId': 'OG003'}, {'value': '34.83', 'spread': '5.854', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '31.83', 'spread': '6.791', 'groupId': 'OG000'}, {'value': '35.03', 'spread': '5.080', 'groupId': 'OG001'}, {'value': '36.27', 'spread': '5.541', 'groupId': 'OG002'}, {'value': '34.77', 'spread': '7.503', 'groupId': 'OG003'}, {'value': '36.09', 'spread': '7.021', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '32.20', 'spread': '5.874', 'groupId': 'OG000'}, {'value': '36.13', 'spread': '4.392', 'groupId': 'OG001'}, {'value': '36.32', 'spread': '5.852', 'groupId': 'OG002'}, {'value': '34.02', 'spread': '6.845', 'groupId': 'OG003'}, {'value': '36.97', 'spread': '5.193', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '33.13', 'spread': '6.369', 'groupId': 'OG000'}, {'value': '35.04', 'spread': '4.876', 'groupId': 'OG001'}, {'value': '35.27', 'spread': '4.077', 'groupId': 'OG002'}, {'value': '35.28', 'spread': '7.642', 'groupId': 'OG003'}, {'value': '37.59', 'spread': '4.453', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '32.88', 'spread': '4.380', 'groupId': 'OG000'}, {'value': '33.21', 'spread': '3.305', 'groupId': 'OG001'}, {'value': '34.22', 'spread': '4.704', 'groupId': 'OG002'}, {'value': '35.69', 'spread': '6.808', 'groupId': 'OG003'}, {'value': '39.16', 'spread': '5.797', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '34.41', 'spread': '6.210', 'groupId': 'OG000'}, {'value': '31.84', 'spread': '4.979', 'groupId': 'OG001'}, {'value': '34.08', 'spread': '3.930', 'groupId': 'OG002'}, {'value': '32.88', 'spread': '5.865', 'groupId': 'OG003'}, {'value': '37.59', 'spread': '4.620', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '31.61', 'spread': '4.440', 'groupId': 'OG000'}, {'value': '31.14', 'spread': '5.035', 'groupId': 'OG001'}, {'value': '32.48', 'spread': '4.043', 'groupId': 'OG002'}, {'value': '31.51', 'spread': '6.288', 'groupId': 'OG003'}, {'value': '35.01', 'spread': '2.773', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Small Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '48.02', 'spread': '19.760', 'groupId': 'OG000'}, {'value': '38.97', 'spread': '17.319', 'groupId': 'OG001'}, {'value': '36.84', 'spread': '16.561', 'groupId': 'OG002'}, {'value': '36.69', 'spread': '18.980', 'groupId': 'OG003'}, {'value': '28.94', 'spread': '18.740', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '54.04', 'spread': '18.566', 'groupId': 'OG000'}, {'value': '30.55', 'spread': '13.832', 'groupId': 'OG001'}, {'value': '29.98', 'spread': '22.143', 'groupId': 'OG002'}, {'value': '26.65', 'spread': '12.759', 'groupId': 'OG003'}, {'value': '23.56', 'spread': '12.336', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '50.14', 'spread': '17.239', 'groupId': 'OG000'}, {'value': '28.86', 'spread': '11.540', 'groupId': 'OG001'}, {'value': '20.91', 'spread': '14.011', 'groupId': 'OG002'}, {'value': '23.23', 'spread': '10.315', 'groupId': 'OG003'}, {'value': '20.94', 'spread': '14.117', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '55.32', 'spread': '16.242', 'groupId': 'OG000'}, {'value': '44.25', 'spread': '18.962', 'groupId': 'OG001'}, {'value': '24.22', 'spread': '15.588', 'groupId': 'OG002'}, {'value': '25.43', 'spread': '14.978', 'groupId': 'OG003'}, {'value': '21.39', 'spread': '12.817', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '50.04', 'spread': '19.344', 'groupId': 'OG000'}, {'value': '57.12', 'spread': '20.032', 'groupId': 'OG001'}, {'value': '34.65', 'spread': '14.144', 'groupId': 'OG002'}, {'value': '28.56', 'spread': '16.992', 'groupId': 'OG003'}, {'value': '24.69', 'spread': '14.503', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '51.82', 'spread': '22.057', 'groupId': 'OG000'}, {'value': '57.12', 'spread': '22.475', 'groupId': 'OG001'}, {'value': '42.09', 'spread': '12.780', 'groupId': 'OG002'}, {'value': '35.91', 'spread': '16.296', 'groupId': 'OG003'}, {'value': '18.81', 'spread': '12.118', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '50.44', 'spread': '24.319', 'groupId': 'OG000'}, {'value': '48.44', 'spread': '15.108', 'groupId': 'OG001'}, {'value': '46.30', 'spread': '90.153', 'groupId': 'OG002'}, {'value': '39.72', 'spread': '18.003', 'groupId': 'OG003'}, {'value': '27.71', 'spread': '17.448', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Medium Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '43.84', 'spread': '31.720', 'groupId': 'OG000'}, {'value': '31.89', 'spread': '16.142', 'groupId': 'OG001'}, {'value': '21.82', 'spread': '12.659', 'groupId': 'OG002'}, {'value': '32.02', 'spread': '20.966', 'groupId': 'OG003'}, {'value': '34.56', 'spread': '28.586', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '45.18', 'spread': '33.883', 'groupId': 'OG000'}, {'value': '29.93', 'spread': '12.067', 'groupId': 'OG001'}, {'value': '31.38', 'spread': '25.580', 'groupId': 'OG002'}, {'value': '34.84', 'spread': '26.305', 'groupId': 'OG003'}, {'value': '33.91', 'spread': '26.636', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '42.08', 'spread': '30.055', 'groupId': 'OG000'}, {'value': '32.32', 'spread': '16.184', 'groupId': 'OG001'}, {'value': '35.10', 'spread': '20.188', 'groupId': 'OG002'}, {'value': '39.47', 'spread': '22.121', 'groupId': 'OG003'}, {'value': '30.62', 'spread': '17.768', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '54.42', 'spread': '43.631', 'groupId': 'OG000'}, {'value': '38.26', 'spread': '25.474', 'groupId': 'OG001'}, {'value': '19.35', 'spread': '9.353', 'groupId': 'OG002'}, {'value': '29.31', 'spread': '18.029', 'groupId': 'OG003'}, {'value': '26.48', 'spread': '18.798', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '40.91', 'spread': '29.614', 'groupId': 'OG000'}, {'value': '39.62', 'spread': '26.490', 'groupId': 'OG001'}, {'value': '25.31', 'spread': '19.813', 'groupId': 'OG002'}, {'value': '34.01', 'spread': '20.440', 'groupId': 'OG003'}, {'value': '25.04', 'spread': '19.770', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '46.29', 'spread': '48.067', 'groupId': 'OG000'}, {'value': '35.02', 'spread': '23.457', 'groupId': 'OG001'}, {'value': '21.05', 'spread': '16.456', 'groupId': 'OG002'}, {'value': '38.27', 'spread': '28.436', 'groupId': 'OG003'}, {'value': '24.48', 'spread': '15.117', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '31.68', 'spread': '26.579', 'groupId': 'OG000'}, {'value': '33.54', 'spread': '19.946', 'groupId': 'OG001'}, {'value': '30.74', 'spread': '24.781', 'groupId': 'OG002'}, {'value': '38.25', 'spread': '33.529', 'groupId': 'OG003'}, {'value': '30.55', 'spread': '35.729', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Large Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '4.66', 'spread': '7.571', 'groupId': 'OG000'}, {'value': '3.91', 'spread': '3.291', 'groupId': 'OG001'}, {'value': '2.43', 'spread': '3.119', 'groupId': 'OG002'}, {'value': '5.18', 'spread': '5.910', 'groupId': 'OG003'}, {'value': '4.63', 'spread': '8.128', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '2.84', 'spread': '3.086', 'groupId': 'OG000'}, {'value': '3.69', 'spread': '3.202', 'groupId': 'OG001'}, {'value': '2.36', 'spread': '2.425', 'groupId': 'OG002'}, {'value': '5.58', 'spread': '6.071', 'groupId': 'OG003'}, {'value': '3.19', 'spread': '4.364', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '4.07', 'spread': '4.367', 'groupId': 'OG000'}, {'value': '3.65', 'spread': '3.692', 'groupId': 'OG001'}, {'value': '2.52', 'spread': '3.384', 'groupId': 'OG002'}, {'value': '2.75', 'spread': '2.821', 'groupId': 'OG003'}, {'value': '4.01', 'spread': '7.348', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '6.72', 'spread': '7.795', 'groupId': 'OG000'}, {'value': '3.85', 'spread': '3.261', 'groupId': 'OG001'}, {'value': '2.17', 'spread': '2.615', 'groupId': 'OG002'}, {'value': '4.27', 'spread': '3.359', 'groupId': 'OG003'}, {'value': '3.91', 'spread': '6.648', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '5.93', 'spread': '6.572', 'groupId': 'OG000'}, {'value': '3.25', 'spread': '2.712', 'groupId': 'OG001'}, {'value': '2.47', 'spread': '3.347', 'groupId': 'OG002'}, {'value': '5.57', 'spread': '7.217', 'groupId': 'OG003'}, {'value': '3.31', 'spread': '4.728', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.41', 'spread': '12.714', 'groupId': 'OG000'}, {'value': '3.42', 'spread': '3.224', 'groupId': 'OG001'}, {'value': '2.13', 'spread': '3.096', 'groupId': 'OG002'}, {'value': '6.33', 'spread': '8.829', 'groupId': 'OG003'}, {'value': '2.51', 'spread': '3.305', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '9.00', 'spread': '15.067', 'groupId': 'OG000'}, {'value': '4.08', 'spread': '3.494', 'groupId': 'OG001'}, {'value': '2.34', 'spread': '2.993', 'groupId': 'OG002'}, {'value': '6.68', 'spread': '9.279', 'groupId': 'OG003'}, {'value': '2.89', 'spread': '3.806', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Total Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '96.56', 'spread': '37.874', 'groupId': 'OG000'}, {'value': '74.79', 'spread': '27.473', 'groupId': 'OG001'}, {'value': '61.11', 'spread': '26.738', 'groupId': 'OG002'}, {'value': '73.92', 'spread': '40.221', 'groupId': 'OG003'}, {'value': '68.14', 'spread': '37.104', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '102.08', 'spread': '40.769', 'groupId': 'OG000'}, {'value': '64.16', 'spread': '24.573', 'groupId': 'OG001'}, {'value': '63.68', 'spread': '44.340', 'groupId': 'OG002'}, {'value': '67.07', 'spread': '36.861', 'groupId': 'OG003'}, {'value': '60.66', 'spread': '33.367', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '96.27', 'spread': '42.925', 'groupId': 'OG000'}, {'value': '64.85', 'spread': '23.841', 'groupId': 'OG001'}, {'value': '58.53', 'spread': '26.727', 'groupId': 'OG002'}, {'value': '65.47', 'spread': '29.936', 'groupId': 'OG003'}, {'value': '55.53', 'spread': '23.928', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '116.48', 'spread': '59.693', 'groupId': 'OG000'}, {'value': '86.36', 'spread': '40.242', 'groupId': 'OG001'}, {'value': '45.72', 'spread': '20.487', 'groupId': 'OG002'}, {'value': '58.99', 'spread': '29.746', 'groupId': 'OG003'}, {'value': '51.76', 'spread': '26.621', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '96.89', 'spread': '39.372', 'groupId': 'OG000'}, {'value': '100.00', 'spread': '44.554', 'groupId': 'OG001'}, {'value': '62.46', 'spread': '29.705', 'groupId': 'OG002'}, {'value': '68.13', 'spread': '29.699', 'groupId': 'OG003'}, {'value': '53.04', 'spread': '31.259', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '106.51', 'spread': '66.108', 'groupId': 'OG000'}, {'value': '95.55', 'spread': '40.252', 'groupId': 'OG001'}, {'value': '65.25', 'spread': '27.024', 'groupId': 'OG002'}, {'value': '80.51', 'spread': '45.939', 'groupId': 'OG003'}, {'value': '45.81', 'spread': '24.781', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '91.11', 'spread': '38.064', 'groupId': 'OG000'}, {'value': '86.06', 'spread': '31.763', 'groupId': 'OG001'}, {'value': '79.37', 'spread': '39.806', 'groupId': 'OG002'}, {'value': '84.64', 'spread': '50.216', 'groupId': 'OG003'}, {'value': '61.16', 'spread': '42.496', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'High Density Lipoprotein-Cholesterol (HDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.73', 'spread': '0.454', 'groupId': 'OG000'}, {'value': '8.81', 'spread': '0.359', 'groupId': 'OG001'}, {'value': '9.02', 'spread': '0.421', 'groupId': 'OG002'}, {'value': '8.88', 'spread': '0.513', 'groupId': 'OG003'}, {'value': '9.01', 'spread': '0.427', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.72', 'spread': '0.356', 'groupId': 'OG000'}, {'value': '8.75', 'spread': '0.364', 'groupId': 'OG001'}, {'value': '9.06', 'spread': '0.371', 'groupId': 'OG002'}, {'value': '8.95', 'spread': '0.427', 'groupId': 'OG003'}, {'value': '9.04', 'spread': '0.425', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.73', 'spread': '0.379', 'groupId': 'OG000'}, {'value': '8.84', 'spread': '0.331', 'groupId': 'OG001'}, {'value': '8.99', 'spread': '0.362', 'groupId': 'OG002'}, {'value': '8.92', 'spread': '0.471', 'groupId': 'OG003'}, {'value': '9.07', 'spread': '0.412', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.75', 'spread': '0.406', 'groupId': 'OG000'}, {'value': '8.85', 'spread': '0.369', 'groupId': 'OG001'}, {'value': '9.05', 'spread': '0.470', 'groupId': 'OG002'}, {'value': '9.03', 'spread': '0.479', 'groupId': 'OG003'}, {'value': '9.09', 'spread': '0.342', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.73', 'spread': '0.398', 'groupId': 'OG000'}, {'value': '8.77', 'spread': '0.384', 'groupId': 'OG001'}, {'value': '8.98', 'spread': '0.419', 'groupId': 'OG002'}, {'value': '8.95', 'spread': '0.547', 'groupId': 'OG003'}, {'value': '9.04', 'spread': '0.403', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.75', 'spread': '0.303', 'groupId': 'OG000'}, {'value': '8.77', 'spread': '0.307', 'groupId': 'OG001'}, {'value': '9.01', 'spread': '0.441', 'groupId': 'OG002'}, {'value': '8.96', 'spread': '0.571', 'groupId': 'OG003'}, {'value': '8.96', 'spread': '0.386', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '8.68', 'spread': '0.339', 'groupId': 'OG000'}, {'value': '8.76', 'spread': '0.263', 'groupId': 'OG001'}, {'value': '9.05', 'spread': '0.484', 'groupId': 'OG002'}, {'value': '8.99', 'spread': '0.507', 'groupId': 'OG003'}, {'value': '9.08', 'spread': '0.395', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}, {'type': 'SECONDARY', 'title': 'Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'OG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '48.57', 'spread': '6.907', 'groupId': 'OG000'}, {'value': '51.21', 'spread': '5.290', 'groupId': 'OG001'}, {'value': '50.15', 'spread': '8.341', 'groupId': 'OG002'}, {'value': '51.37', 'spread': '6.934', 'groupId': 'OG003'}, {'value': '50.07', 'spread': '6.934', 'groupId': 'OG004'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '48.13', 'spread': '4.918', 'groupId': 'OG000'}, {'value': '52.85', 'spread': '5.284', 'groupId': 'OG001'}, {'value': '53.57', 'spread': '10.417', 'groupId': 'OG002'}, {'value': '53.47', 'spread': '8.371', 'groupId': 'OG003'}, {'value': '50.54', 'spread': '5.837', 'groupId': 'OG004'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '52.42', 'spread': '6.876', 'groupId': 'OG000'}, {'value': '54.09', 'spread': '6.152', 'groupId': 'OG001'}, {'value': '54.28', 'spread': '9.695', 'groupId': 'OG002'}, {'value': '50.22', 'spread': '4.799', 'groupId': 'OG003'}, {'value': '53.95', 'spread': '8.878', 'groupId': 'OG004'}]}]}, {'title': 'Day 36', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '51.42', 'spread': '7.249', 'groupId': 'OG000'}, {'value': '51.81', 'spread': '6.030', 'groupId': 'OG001'}, {'value': '53.69', 'spread': '10.745', 'groupId': 'OG002'}, {'value': '55.33', 'spread': '9.556', 'groupId': 'OG003'}, {'value': '52.40', 'spread': '9.080', 'groupId': 'OG004'}]}]}, {'title': 'Day 50', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '51.57', 'spread': '9.261', 'groupId': 'OG000'}, {'value': '47.62', 'spread': '4.463', 'groupId': 'OG001'}, {'value': '53.62', 'spread': '15.032', 'groupId': 'OG002'}, {'value': '52.48', 'spread': '9.738', 'groupId': 'OG003'}, {'value': '54.14', 'spread': '10.801', 'groupId': 'OG004'}]}]}, {'title': 'Day 64', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '50.51', 'spread': '9.062', 'groupId': 'OG000'}, {'value': '46.58', 'spread': '6.099', 'groupId': 'OG001'}, {'value': '48.60', 'spread': '7.661', 'groupId': 'OG002'}, {'value': '52.95', 'spread': '8.965', 'groupId': 'OG003'}, {'value': '51.74', 'spread': '5.163', 'groupId': 'OG004'}]}]}, {'title': 'Day 78', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '52.17', 'spread': '11.873', 'groupId': 'OG000'}, {'value': '48.95', 'spread': '4.820', 'groupId': 'OG001'}, {'value': '49.41', 'spread': '7.249', 'groupId': 'OG002'}, {'value': '50.99', 'spread': '8.967', 'groupId': 'OG003'}, {'value': '49.63', 'spread': '6.762', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78', 'unitOfMeasure': 'nm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacodynamic analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 pharmacodynamic parameter. Here 'n' signifies those participants who were evaluable at the specified time points for each reporting group, respectively."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'FG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'FG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'FG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'FG004', 'title': 'PF-04950615 1.5 mg/kg', 'description': 'Participants received PF-04950615 1.5 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '14'}, {'groupId': 'FG003', 'numSubjects': '14'}, {'groupId': 'FG004', 'numSubjects': '14'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '14'}, {'groupId': 'FG003', 'numSubjects': '13'}, {'groupId': 'FG004', 'numSubjects': '14'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '13'}, {'groupId': 'FG003', 'numSubjects': '12'}, {'groupId': 'FG004', 'numSubjects': '14'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Randomized but not treated', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '14', 'groupId': 'BG002'}, {'value': '13', 'groupId': 'BG003'}, {'value': '14', 'groupId': 'BG004'}, {'value': '67', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'Participants received placebo matched to PF-04950615 once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'BG001', 'title': 'PF-04950615 0.25 mg/kg', 'description': 'Participants received PF-04950615 0.25 milligram per kilogram (mg/kg), intravenous (IV) infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'BG002', 'title': 'PF-04950615 0.50 mg/kg', 'description': 'Participants received PF-04950615 0.50 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'BG003', 'title': 'PF-04950615 1.0 mg/kg', 'description': 'Participants received PF-04950615 1.0 mg/kg, IV infusion once daily on Day 1, 8, 15 and 22 in 28 days treatment period.'}, {'id': 'BG004', 'title': 'PF-04950615 1.50 mg/kg', 'description': 'Participants received a single dose of PF-04950615 1.50 milligram/kilogram (mg/kg), intravenous (IV) infusion once on Day 1,8,15 and 22.'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '55.3', 'spread': '13.7', 'groupId': 'BG000'}, {'value': '52.0', 'spread': '7.8', 'groupId': 'BG001'}, {'value': '51.5', 'spread': '13.0', 'groupId': 'BG002'}, {'value': '52.5', 'spread': '14.3', 'groupId': 'BG003'}, {'value': '55.1', 'spread': '8.8', 'groupId': 'BG004'}, {'value': '53.2', 'spread': '11.5', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '27', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '40', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of study drug.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 68}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-08', 'completionDateStruct': {'date': '2011-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-08-08', 'studyFirstSubmitDate': '2010-11-03', 'resultsFirstSubmitDate': '2017-09-08', 'studyFirstSubmitQcDate': '2010-11-16', 'lastUpdatePostDateStruct': {'date': '2019-01-22', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-08-08', 'studyFirstPostDateStruct': {'date': '2010-11-18', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-01-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2011-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Dose Limiting and Intolerable Treatment-Related Adverse Events (AEs)', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Dose limiting and intolerable treatment-related AEs were the AEs resulting from drug overdose, drug withdrawal, drug abuse, drug misuse, drug interactions, drug dependency, extravasation, exposure in utero, exposure during breast feeding.'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-Related Adverse Events (AEs)', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to Day 78 that were absent before treatment or that worsened relative to pretreatment state.'}, {'measure': 'Number of Participants With Adverse Events (AEs) by Severity', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug. AE was assessed according to common terminology criteria for adverse events (CTCAE) version 4.0 severity grades- Grade 1: mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2: moderate (minimal, local or non invasive intervention indicated); Grade 3: severe (medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling); Grade 4: Life-threatening consequences; urgent intervention indicated and Grade 5: Death related to AE.'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'Criteria: Haemoglobin(Hgb), hematocrit, RBC: \\<0.8\\*lower limit of normal(LLN),mean corpuscular volume, mean corpuscular Hgb concentration \\<0.9\\*LLN or\\>1.1\\*upper limit of normal(ULN), platelet\\<0.5\\*LLN or\\>1.75\\*ULN, WBC\\<0.6\\*LLN or\\>1.5\\*ULN, lymphocyte, neutrophil\\<0.8\\*LLN or\\>1.2\\*ULN, basophil, eosinophil, monocyte\\>1.2\\*ULN; bilirubin\\>1.5\\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase, lactate dehydrogenase\\>3.0\\*ULN,total protein,albumin\\<0.8\\*LLN or\\>1.2\\*ULN; blood urea nitrogen, creatinine\\>1.3\\*ULN,uric acid\\>1.2\\*ULN;sodium\\<0.95\\*LLNor\\>1.05\\*ULN,potassium,chloride,calcium,bicarbonate\\<0.9\\*LLN or\\>1.1\\*ULN; glucose\\<0.6\\*LLN or \\>1.5\\*ULN, urine specific gravity\\<1.003 or\\>1.030,urine pH\\<4.5or\\>8,urine glucose, ketones, urine protein,urine blood/Hgb,urobilinogen,bilirubin,nitrite, leukocyte esterase\\>=1; urine RBC,WBC\\>=20,urine epithelial cells\\>=6,urine granular casts,hyaline casts\\>1,urine bacteria\\>20,partial thromboplastin time,prothrombin:\\>1.1\\*ULN.'}, {'measure': 'Number of Participants With Clinically Relevant Changes in Vital Signs', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'Criteria for clinically relevant vital signs: supine and standing systolic blood pressure (SBP): less than (\\<) 90 millimeter of mercury (mmHg); supine and standing diastolic blood pressure (DBP): \\<50 mmHg. Maximum increase from baseline (IFB) or decrease from baseline (DFB) in supine and standing SBP: greater than or equal to (\\>=) 30 mmHg and maximum IFB or DFB in supine and standing DBP: \\>=20 mmHg. Supine pulse rate: \\<40 and greater than (\\>) 120 beats per minute (bpm); standing pulse rate: \\<40 and \\>140 bpm.'}, {'measure': 'Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Parameters', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': "Criteria for clinically relevant ECG parameters: PR interval: maximum IFB of \\>=25 percent or 50 percent; QRS complex: maximum IFB of \\>=25 or 50 percent; QTcF interval (Fridericia's Correction): maximum IFB of \\>=30 millisecond (msec) to \\<60 msec and maximum IFB of \\>=60 msec."}, {'measure': 'Number of Participants With Anti-drug Antibodies (ADA)', 'timeFrame': 'Baseline up to Follow-up period (Day 78)', 'description': 'The number of participants with at least one positive ADA were summarized for each treatment arm. Participants with positive antibody titer of \\>4.32 milligram/milliliter (mg/mL) were considered as ADA positive.'}], 'secondaryOutcomes': [{'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'AUCtau is area under the concentration-time profile from time zero to time tau (τ), the dosing interval, where tau =168 hours.'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'Tmax is the time at which maximum plasma concentration (Cmax) occurred.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of PF-04950615', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose'}, {'measure': 'Plasma Decay Half-Life (t1/2) of PF-04950615', 'timeFrame': 'Day 1 and 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 't1/2 was the time measured for the plasma concentration of PF-04950615 to decrease by one half. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.'}, {'measure': 'Apparent Clearance (CL) of PF-04950615', 'timeFrame': 'Day 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'CL was calculated as Dose/AUCtau. AUCtau is area under the concentration-time profile from time zero to time tau, the dosing interval, where tau=168 hours.'}, {'measure': 'Volume of Distribution at Steady State (Vss) of PF-04950615', 'timeFrame': 'Day 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'Vss was calculated as CL\\*MRT. CL was calculated as Dose/AUCtau, where AUCtau was area under the concentration-time profile from time zero to time tau (τ), the dosing interval, where tau=168 hours. MRT was mean residence time (predicted) extrapolated to infinity.'}, {'measure': 'Accumulation Ratio (Rac) of PF-04950615', 'timeFrame': 'Day 22: pre-dose and 1, 6, 9, 24 and 72 hours post dose', 'description': 'Rac was calculated as Day 22 AUCtau divided by Day 1 AUCtau, where AUCtau is area under the concentration-time profile from time zero to time tau (τ), the dosing interval, where tau =168 hours.'}, {'measure': 'Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78'}, {'measure': 'Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Day 8, 15, 22, 29 and 78'}, {'measure': 'Number of Participants Achieving LDL-C Less Than (<) 70 Milligram Per Deciliter (mg/dL)', 'timeFrame': 'Day 15, 22, 29 and 36'}, {'measure': 'Number of Participants Achieving LDL-C Less Than (<) 100 Milligram Per Deciliter (mg/dL)', 'timeFrame': 'Day 15, 22, 29 and 36'}, {'measure': 'Number of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in LDL-C From Baseline', 'timeFrame': 'Baseline, Day 15, 22, 29 and 36'}, {'measure': 'Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78'}, {'measure': 'Change From Baseline in Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78'}, {'measure': 'Change From Baseline in Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78'}, {'measure': 'Change From Baseline in Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78'}, {'measure': 'Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78'}, {'measure': 'Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 29 and 78'}, {'measure': 'Percent Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Day 8, 15, 22, 29 and 78'}, {'measure': 'Percent Change From Baseline In Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Day 8, 15, 22, 29 and 78'}, {'measure': 'Percent Change From Baseline In Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Day 8, 15, 22, 29 and 78'}, {'measure': 'Percent Change From Baseline In Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Day 8, 15, 22, 29 and 78'}, {'measure': 'Percent Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Day 8, 15, 22, 29 and 78'}, {'measure': 'Percent Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78', 'timeFrame': 'Day 8, 15, 22, 29 and 78'}, {'measure': 'Change From Baseline In Low Density Lipoprotein Cholesterol (LDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Change From Baseline In Small Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Change From Baseline In Medium Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Change From Baseline In Large Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Change From Baseline In Total Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Levels at Baseline, Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Baseline, Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'C-Reactive Protein Levels at Day 8, 15, 21, 36, 57 and 78', 'timeFrame': 'Day 8, 15, 21, 36, 57 and 78'}, {'measure': 'Small High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Medium High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Large High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Total High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Small Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Medium Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Large Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Total Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'High Density Lipoprotein-Cholesterol (HDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}, {'measure': 'Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78', 'timeFrame': 'Day 8, 15, 22, 36, 50, 64 and 78'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Hypercholesterolemia', 'Dyslipidemia', 'LDL', 'High Cholesterol', 'Japanese Volunteers', 'PF-04950615', 'RN316'], 'conditions': ['Hypercholesterolemia', 'Dyslipidemia']}, 'referencesModule': {'references': [{'pmid': '37994400', 'type': 'DERIVED', 'citation': 'Wang EQ, Kaila N, Plowchalk D, Gibiansky L, Yunis C, Sweeney K. Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2013-2026. doi: 10.1002/psp4.13050. Epub 2023 Nov 22.'}, {'pmid': '29037448', 'type': 'DERIVED', 'citation': 'Wan H, Gumbiner B, Joh T, Riel T, Udata C, Forgues P, Garzone PD. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects. Clin Ther. 2017 Nov;39(11):2243-2259.e5. doi: 10.1016/j.clinthera.2017.09.009. Epub 2017 Oct 14.'}, {'pmid': '28181260', 'type': 'DERIVED', 'citation': 'Udata C, Garzone PD, Gumbiner B, Joh T, Liang H, Liao KH, Williams JH, Meng X. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development. J Clin Pharmacol. 2017 Jul;57(7):855-864. doi: 10.1002/jcph.867. Epub 2017 Feb 9.'}], 'seeAlsoLinks': [{'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481009&StudyName=Safety%20And%20Tolerability%20Of%20Multiple%20Doses%20Of%20PF-04950615%20%28RN316%29%20In%20Subjects%20With%20Hypercholesterolemia', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* LDL-C must be greater or equal to 130 mg/dl\n* BMI must be between 18.5 and 40 kg/m2\n* Japanese volunteers must have 4 Japanese grand parents born in Japan\n\nExclusion Criteria:\n\n* History of cardiovascular or cerebrovascular event during the past year.\n* Poorly controlled type 1 or type 2 diabetes mellitus\n* Subjects who have taken lipid lowering therapies within the last 3 months of screening.'}, 'identificationModule': {'nctId': 'NCT01243151', 'briefTitle': 'Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia', 'orgStudyIdInfo': {'id': 'B1481009'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'A', 'interventionNames': ['Biological: PF-04950615 (RN316)']}, {'type': 'EXPERIMENTAL', 'label': 'B', 'interventionNames': ['Biological: PF-04950615 (RN316)']}, {'type': 'EXPERIMENTAL', 'label': 'C', 'interventionNames': ['Biological: PF-04950615 (RN316)']}, {'type': 'EXPERIMENTAL', 'label': 'D', 'interventionNames': ['Biological: PF-04950615 (RN316)']}, {'type': 'EXPERIMENTAL', 'label': 'E', 'interventionNames': ['Biological: PF-04950615 (RN316)']}], 'interventions': [{'name': 'PF-04950615 (RN316)', 'type': 'BIOLOGICAL', 'description': 'Infusion every week', 'armGroupLabels': ['A']}, {'name': 'PF-04950615 (RN316)', 'type': 'BIOLOGICAL', 'description': 'Infusion every week', 'armGroupLabels': ['B']}, {'name': 'PF-04950615 (RN316)', 'type': 'BIOLOGICAL', 'description': 'Infusion every week', 'armGroupLabels': ['C']}, {'name': 'PF-04950615 (RN316)', 'type': 'BIOLOGICAL', 'description': 'Infusion every week', 'armGroupLabels': ['D']}, {'name': 'PF-04950615 (RN316)', 'type': 'BIOLOGICAL', 'description': 'Infusion every week', 'armGroupLabels': ['E']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90232', 'city': 'Culver City', 'state': 'California', 'country': 'United States', 'facility': 'California Clinical Trials Medical Group', 'geoPoint': {'lat': 34.02112, 'lon': -118.39647}}, {'zip': '91206', 'city': 'Glendale', 'state': 'California', 'country': 'United States', 'facility': 'Glendale Adventist Medical Center', 'geoPoint': {'lat': 34.14251, 'lon': -118.25508}}, {'zip': '33126', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'SeaView Research, Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33134', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'SeaView Research, Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '96813', 'city': 'Honolulu', 'state': 'Hawaii', 'country': 'United States', 'facility': 'Covance Clinical Research Unit, Inc.', 'geoPoint': {'lat': 21.30694, 'lon': -157.85833}}, {'zip': '66211', 'city': 'Overland Park', 'state': 'Kansas', 'country': 'United States', 'facility': 'Vince and Associates Clinical Research', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}, {'zip': '66212', 'city': 'Overland Park', 'state': 'Kansas', 'country': 'United States', 'facility': 'Vince and Associates Clinical Research', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}, {'zip': '55114', 'city': 'Saint Paul', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Prism Research', 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'zip': '78209', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Healthcare Discoveries, LLC dba ICON Development Solutions', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}